Oral dosage forms of TRbeta agonist VK2809 for treatment of liver disorders and methods of making them

By using solid amorphous spray-drying dispersion technology and a combination of polymers in TRβ agonists, the stability and exposure of existing TRβ agonists in room temperature storage are solved, and higher drug stability and bioavailability are achieved .

CN119072316APending Publication Date: 2024-12-03VIKING THERAPEUTICS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380034572.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-02-22
Filing Date
2023-02-13
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

Due to poor solubility and stability problems, existing TRβ agonists are difficult to store at room temperature, and have a high exposure risk during preparation, which affects the effectiveness and safety of the drug.

Method used

Using solid amorphous spray-dried dispersion (SDD) instant-release tablet preparation containing Compound 1, combined with polymers such as PVP-VA and ductile filler microcrystalline cellulose, to form oral dosage forms, to improve the drug by spray-drying dispersion technology Water solubility and stability ensure stability in storage at room temperature.

Benefits of technology

The stability improvement and exposure matching of TRβ agonists is achieved or surpassed the current formulation, ensuring chemical stability and bioavailability for long-term storage under room temperature conditions, reducing the risk of drug degradation.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119072316A_ABST
    Figure CN119072316A_ABST
Patent Text Reader

Abstract

The present disclosure relates to oral dosage forms of the TRbeta agonist VK2809 and methods of making the same. The present disclosure provides oral dosage forms of VK2809 with improved stability and solubility characteristics that allow storage under normal conditions by using spray drying with one or more polymers, the polymer is selected from the group consisting of: polyvinylpyrrolidone (PVP), polyvinylpyrrolidone-vinyl acetate copolymer (PVP-VA), polyvinyl alcohol (PVA), polyacrylic acid (PAA), polyethylene oxide (PEO), hydroxy propyl cellulose (HPC), hydroxypropyl methyl cellulose (HPMC), copovidone, poloxamer 407, hydroxypropyl methylcellulose acetate succinate (HPMCAS), polyacrylates, and combinations thereof.
Need to check novelty before this filing date? Find Prior Art

Description

field

[0001] The compositions and methods of the present disclosure generally relate to the field of oral dosage forms of thyroid hormone receptor-β (TRβ) agonists for the treatment of liver disorders, fibrotic diseases, and inflammation. background

[0002] Thyroid hormone (TH) is synthesized in the thyroid gland in response to thyroid stimulating hormone (TSH), which is secreted by the pituitary in response to various stimuli (e.g., thyrotropin-releasing hormone (TRH) from the hypothalamus). Thyroid hormone is an iodinated O-aryltyrosine analogue that is secreted into the circulation primarily as 3,3',5,5'-tetraiodothyronine (T4). T4 is rapidly deiodinated to 3,3',5'-triiodothyronine (T3) by thyroxine 5'-deiodinase in local tissues, which is the most effective TH. T3 is metabolized to inactive metabolites via a variety of pathways, including pathways involving deiodination, glucuronidation, sulfation, deamination, and decarboxylation. Most of the circulating T4 and T3 are eliminated by the liver.

[0003] The biological activity of TH is mainly mediated by the thyroid hormone receptor (TR). TR belongs to the nuclear receptor superfamily, and together with its common partner, the retinoid X receptor, forms a heterodimer that acts as a ligand-induced transcription factor. Like other nuclear receptors, TR has a ligand binding domain and a DNA binding domain, and regulates gene expression through ligand-dependent interactions with DNA response elements (thyroid response elements, TRE). Currently, the literature shows that TR is encoded by two different genes (TRα and TRβ), which produce several isoforms through alternative splicing (Williams, Mol. Cell. Biol. 20 (22): 8329-42 (2000); Nagaya et al., Biochem. Biophys. Res. Commun. 226 (2): 426-30 (1996)). The main isoforms identified so far are TRα-1, TRα-2, TRβ-1 and TRβ-2. TRα-1 is ubiquitously expressed in rats, with highest expression in skeletal muscle and brown fat. TRβ-1 is also ubiquitously expressed, with highest expression in the liver, brain, and kidney. TRβ-2 is expressed in specific regions of the anterior pituitary and hypothalamus, as well as in the developing brain and inner ear. In rat and mouse liver, TRβ-1 is the predominant isoform (80%). The TR isoforms found in humans and rats are highly homologous in their amino acid sequences, suggesting that each has a specific function.

[0004] TH affects the growth, metabolism and physiological functions of almost all organs. TH lowers serum cholesterol and triglycerides. However, side effects of TH function include arrhythmias, bone loss, nervousness and anxiety.

[0005] TRβ agonists can be used as therapeutic agents for conditions such as hepatitis, nonalcoholic fatty liver disease, nonalcoholic steatohepatitis (NASH), and a variety of fibrotic diseases and disorders. However, some TRβ agonists may be poorly soluble and / or have undesirable stability characteristics. The low water solubility and poor stability of such compounds may require special storage conditions for the compounds, and there may be challenges in preparing formulations that provide sufficient exposure to a subject and do not degrade when stored under normal conditions.

[0006] Therefore, there is a need to provide a pharmaceutical formulation that provides a suitable exposure of a poorly water-soluble drug to a subject. In addition, there is a need for a pharmaceutical formulation with improved stability so that the drug does not degrade under ambient conditions and can utilize room temperature storage. Overview

[0007] In a first aspect of the present disclosure, provided herein is an oral dosage form comprising: (A) a composition containing Compound 1 having the following structure: Or a pharmaceutically acceptable salt thereof; and one or more polymers selected from: polyvinyl pyrrolidone (PVP), polyvinyl pyrrolidone-vinyl acetate copolymer (PVP-VA), polyvinyl alcohol (PVA), polyacrylic acid (PAA), polyethylene oxide (PEO), hydroxypropyl cellulose (HPC), hydroxypropyl methylcellulose (HPMC), copolyvidone, poloxamer 407, hydroxypropyl methylcellulose acetate succinate (HPMCAS), polyacrylates and combinations thereof; and (B) one or more ductile fillers, brittle fillers, disintegrants, glidants, lubricants or combinations thereof. In some embodiments, the polymer may be a polyvinyl pyrrolidone-vinyl acetate copolymer (PVP-VA).

[0008] In some embodiments of the first aspect, Compound 1 and one or more polymers can be combined to form a spray dried dispersion. In other embodiments, Compound 1 and one or more polymers can be combined to form a hot melt extrudate.

[0009] In some embodiments of the first aspect, the mass ratio of compound 1 to one or more polymers in the composition may be 1: 10 to 10: 1. In other embodiments, the mass ratio of compound 1 to one or more polymers in the composition may be 1: 1 to 1: 4. In some specific embodiments, the mass ratio of compound 1 to one or more polymers in the composition may be 1: 3.

[0010] In some embodiments of the first aspect, the composition may comprise 5% to 25% by weight of the dosage form. In other embodiments, the composition may comprise 10% to 15% by weight of the dosage form.

[0011] In some embodiments of the first aspect, the ductile filler is selected from microcrystalline cellulose and silicified microcrystalline cellulose. In some specific embodiments, the ductile filler is microcrystalline cellulose.

[0012] In some embodiments of the first aspect, microcrystalline cellulose can account for 40% to 60% by weight of the dosage form. In other embodiments, microcrystalline cellulose can account for 45% to 55% by weight of the dosage form. In some embodiments, microcrystalline cellulose can account for 50% by weight of the dosage form.

[0013] In some embodiments of the first aspect, the brittle filler can comprise lactose monohydrate, spray-dried lactose, anhydrous lactose, lactose monohydrate, anhydrous lactose, mannitol, and combinations thereof. In some embodiments, the brittle filler can comprise lactose monohydrate, anhydrous lactose, or mannitol.

[0014] In some embodiments of the first aspect, the brittle filler may comprise 10% to 40% by weight of the dosage form. In other embodiments, the brittle filler may comprise 20% to 30% by weight of the dosage form. In some embodiments, the brittle filler may comprise 25% by weight of the dosage form.

[0015] In some embodiments of the first aspect, the disintegrant can be selected from carboxymethylcellulose calcium, sodium carboxymethyl starch, cross-linked sodium carboxymethyl cellulose, starch, pregelatinized starch, sodium starch glycolate, cross-linked polyvinyl pyrrolidone crospovidone, hydroxypropyl cellulose, magnesium aluminum silicate and polyclirin potassium. In some embodiments, the disintegrant can be cross-linked sodium carboxymethyl cellulose or crospovidone.

[0016] In some embodiments of the first aspect, the disintegrant may comprise 5% to 15% by weight of the dosage form. In other embodiments, the disintegrant may comprise 10% by weight of the dosage form.

[0017] In some embodiments of the first aspect, the lubricant can be selected from the group consisting of stearic acid, talc, glyceryl behenate, sodium stearyl fumarate, and magnesium stearate. In some specific embodiments, the lubricant can be magnesium stearate.

[0018] In some embodiments of the first aspect, the lubricant can comprise 0.1% to 3% by weight of the dosage form. In other embodiments, the lubricant can comprise 0.1% to 1% by weight of the dosage form. In some embodiments, the lubricant can comprise 5% by weight of the dosage form.

[0019] In some embodiments of the first aspect, the glidant can be silicon dioxide, starch or talc. In some specific embodiments, the glidant can be silicon dioxide.

[0020] In some embodiments of the first aspect, the glidant comprises 0.1% to 3% by weight of the dosage form. In other embodiments, the glidant may comprise 0.1% to 1% by weight of the dosage form. In some embodiments, the glidant may comprise 5% by weight of the dosage form.

[0021] In some embodiments of the first aspect, the oral dosage form described herein may comprise: (a) an intragranular portion comprising: (i) Compound 1 or a pharmaceutically acceptable salt thereof and one or more polymers; (ii) a ductile filler; (iii) a brittle filler; (iv) a disintegrant; (v) a glidant and (vi) a lubricant; and (b) an extragranular portion comprising (i) a disintegrant and (ii) a lubricant.

[0022] In some embodiments of the first aspect, the dosage form may be characterized by having 90% to 100% of the original amount of Compound 1 after storage for 1 month at 50°C and ambient relative humidity (RH). In other embodiments, the dosage form may be characterized by having 95% to 100% of the original amount of Compound 1 after storage for 1 month at 50°C and ambient relative humidity (RH). In other embodiments, the dosage form may be characterized by having 90% to 100% of the original amount of Compound 1 after storage for 2 months at 50°C and ambient relative humidity (RH). In other embodiments, the dosage form may be characterized by having 95% to 100% of the original amount of Compound 1 after storage for 2 months at 50°C and ambient relative humidity (RH).

[0023] In a second aspect of the present disclosure, provided herein is a method for preparing an oral dosage as described herein, comprising the following steps: (a) preparing a pre-granulation pre-mixture, the pre-granulation pre-mixture comprising (a) a composition comprising Compound 1 and one or more polymers; (ii) a ductile filler; (iii) a brittle filler; (iv) a disintegrant and (v) a glidant; (b) mixing the pre-mixed composition; (c) further adding a lubricant to the pre-granulation pre-mixture; (d) slugging the pre-granulation pre-mixture; and (e) granulating the pre-granulation pre-mixture to form a granular material.

[0024] In some embodiments, the method may further include the following steps: (f) adding a disintegrant to the granulated material; (g) further mixing the granulated material; (h) further adding a lubricant to the granulated material and mixing to form a final mixture; and (i) compressing the final mixture into a dosage form.

[0025] In a third aspect of the present disclosure, provided herein is a method for preventing, treating or ameliorating one or more fatty liver diseases in a subject in need thereof, comprising administering to a subject in need thereof, the method comprising administering to the subject an oral dosage form described herein.

[0026] In some embodiments, the fatty liver disease may be selected from the group consisting of: steatosis, nonalcoholic fatty liver disease, and nonalcoholic steatohepatitis.

[0027] In some embodiments, the method can include administering a second agent. In some embodiments, the second agent can be administered sequentially or simultaneously.

[0028] In some embodiments, the method can result in the prevention, treatment or improvement of fibrosis, fibrotic conditions or fibrotic symptoms. In some embodiments, the method can result in a reduction in the amount of extracellular matrix proteins present in one or more tissues of the object. In some embodiments, the method can result in a reduction in the amount of collagen present in one or more tissues of the object. In some embodiments, the method can result in a reduction in the amount of type I, type Ia or type III collagen present in one or more tissues of the object. BRIEF DESCRIPTION OF THE DRAWINGS

[0028] Figure 1 Shown are the relative scattered absorbance and measured concentration of compound 1 from stock solution into biologically relevant media at 37°C.

[0029] Figure 2 Shown is the dissolution of a spray-dried dispersion of Compound 1 in PBS buffer at pH 6.5 with 0.5% simulated intestinal fluid after exposure to 0.01 N HCl for 30 minutes as measured by a UV-Vis probe. Details

[0030] The present disclosure provides an oral dosage formulation of Compound 1:

[0031] Compound 1 is a low solubility, lipophilic prodrug compound for the treatment of chronic liver diseases including non-alcoholic fatty liver disease (NAFLD). Compound 1 can be prepared according to known methods, including those described in U.S. Patent No. 7,829,552 (which is incorporated herein by reference in its entirety). Current clinical dosage forms are encapsulated PEG-based formulations that provide sufficient exposure, but require cold chain storage due to chemical stability challenges. Provided herein is an immediate release tablet formulation of a solid amorphous spray-dried dispersion (SDD) comprising compound 1, which matches or exceeds the exposure provided by the current formulation, has improved stability, and can be stored at room temperature. definition

[0032] The term "mammal" is used in its ordinary biological sense. Thus, it specifically includes human and non-human mammals, such as dogs, cats, horses, donkeys, mules, cattle, domestic buffalo, camels, llamas, alpacas, bison, yaks, goats, sheep, pigs, moose, deer, domestic antelope and non-human primates, as well as many other species.

[0033] As used herein, "subject" means a human or non-human mammal selected for treatment or therapy, including but not limited to dogs, cats, horses, donkeys, mules, cows, domestic buffalo, camels, llamas, alpacas, bison, yaks, goats, sheep, pigs, moose, deer, domestic antelope, or non-human primates.

[0034] "Subject suspected of having..." means a subject that exhibits one or more clinical indicators of a disease or condition. In certain embodiments, the disease or condition is one or more fibrosis, fibrotic conditions, or fibrotic symptoms. In certain embodiments, the disease or condition is scleroderma. In certain embodiments, the disease or condition is non-alcoholic steatohepatitis (NASH). In certain embodiments, the disease or condition is cirrhosis. In certain embodiments, the disease or condition is non-alcoholic fatty liver disease (NAFLD). In certain embodiments, the disease or condition is idiopathic pulmonary fibrosis. In certain embodiments, the disease or condition is atherosclerosis. In certain embodiments, the disease or condition is hepatitis, alcoholic fatty liver disease, asthma, cardiac fibrosis, organ transplant fibrosis, muscle fibrosis, pancreatic fibrosis, myelofibrosis, liver fibrosis, hepatobiliary cirrhosis, spleen fibrosis, scleroderma, pulmonary fibrosis, diffuse parenchymal lung disease, idiopathic interstitial fibrosis, diffuse interstitial fibrosis; interstitial pneumonia, desquamative interstitial pneumonia, respiratory bronchiolitis, interstitial lung disease, chronic interstitial lung disease, acute interstitial pneumonia, hypersensitivity pneumonitis, nonspecific interstitial pneumonia, cryptogenic organizing pneumonia, lymphocytic interstitial pneumonia, pneumoconiosis, silicosis, emphysema, interstitial fibrosis, sarcoidosis, mediastinal fibrosis, cardiac fibrosis, atrial fibrosis, endomyocardial fibrosis, renal fibrosis, chronic kidney disease, type II diabetes, macular degeneration, keloid lesions, hypertrophy scarring, nephrogenic systemic fibrosis, injection fibrosis, surgical complications, fibrosis in transplanted organs, chronic allograft vasculopathy and / or chronic rejection, fibrosis associated with ischemia-reperfusion injury, post-vasectomy pain syndrome, fibrosis associated with rheumatoid arthritis, arthrofibrosis, Dupuytren's disease, dermatomyositis-polymyositis, mixed connective tissue disease, oral fibroproliferative lesions, fibrotic intestinal strictures, Crohn's disease, glial scarring, leptomeningeal fibrosis, meningitis, systemic lupus erythematosus, fibrosis due to radiation exposure, fibrosis due to cystic rupture of the breast, myelofibrosis, retroperitoneal fibrosis, progressive massive fibrosis or its symptoms or sequelae, or other diseases or conditions that result in excessive deposition of extracellular matrix components.

[0035] As used herein, "fibrosis" refers to the abnormal deposition of extracellular matrix proteins. Such proteins include but are not limited to collagen, elastin, fibronectin, laminin, keratin, keratin sulfate, fibrin, perlecan, agrin or aggrecan. As used herein, "collagen" refers to any subtype of collagen, including but not limited to type I, type II, type III, type IV, type V, type VI, type VII, type VIII, type IX, type X, type XI, type XII, type XIII, type XIV, type XV, type XVI, type XVII or type XVIII. Exemplary collagen types and subtypes especially include type I, type Ia, type II, type III, type IV and type V. As used herein, fibrosis can occur alone or as a symptom or sequela of another condition. As used herein, fibrosis can be caused by genetic conditions, genetic susceptibility, environmental damage, damage, wound healing, autoimmune conditions or chronic inflammation, chronic inflammatory conditions or another condition that causes abnormal or excessive deposition of extracellular matrix components. Fibrosis referred to herein can be assessed by measuring or determining the presence or level of one or more biomarkers. The presence of fibrotic biomarkers includes but is not limited to Col1a1, Col3a1, ACTA2, ENPP and / or LGALS1 genes or any combination thereof or expression of products. The diagnosis or assessment of fibrosis can also be carried out by measuring the presence or level of type I collagen and / or hydroxyproline or any combination thereof or products. The diagnosis or assessment of fibrosis can also be carried out by histological, histochemical or immunohistochemical analysis of one or more samples from the object.

[0036] "Glycogen storage disease" means any one or more of a group of disorders marked by dysfunction in the synthesis, transport, or utilization of glycogen, usually due to loss of essential enzyme activity. Glycogen storage diseases are generally classified by type based on their symptoms and cause. The known types include GSD type 0 (glycogenolysis, glycogen synthase deficiency); GSD type 1 (von Gierke disease, glucose-6-phosphatase translocase / transporter deficiency, GSD I); GSD type 2 (Pompe disease, alpha-1-4-glucosidase deficiency, GSD II); GSD type 3 (Cori disease, Forbes disease, limited dextrinosis, debranching disease; amylo-1-6-glucosidase deficiency due to loss of glucosidase and / or transferase activity, GSD III); GSD type 4 (Anderson disease, glycogen phosphorylase deficiency, branching enzyme deficiency, amyloline disease, glycogen branching enzyme deficiency; amylo-1,4 to 1,6 transglucosidase deficiency, GSD IV); GSD type 5 (McArdle disease; glycogen phosphorylase (muscle type) deficiency, GSD V); GSD GSD type 6 (Hers disease; glycogen phosphorylase E (liver form) deficiency, GSDVI); GSD type 7 (Tarui disease; phosphofructokinase deficiency, GSDVII); GSD types 8 and 9 (GSD with defects in the phosphorylase activation system; phosphorylase kinase (liver or muscle isoform) deficiency, GSDVIII and GSD IX); GSD type 10 (cyclic AMP-dependent kinase deficiency, GSD X); GSD type 11 (Fanconi-Bickel syndrome; glucose transporter type 2 (GLUT2) deficiency, GSD XI) and GSD type 12 (aldolase A deficiency, GSD XII). Subtypes of glycogen storage diseases are also known, particularly GSD 1a, which is caused by a mutation in the glucose-6-phosphatase (G6PC) gene and results in, among other symptoms, excessive accumulation of glycogen and lipids in liver tissue, hepatomegaly, hepatic adenomas and hepatocellular carcinomas. Symptoms of glycogen storage diseases can include elevated or decreased blood sugar, insulin insensitivity, muscle disease, and liver symptoms such as steatosis, hyperlipidemia, hypercholesterolemia, cardiomegaly, hepatomegaly, fibrosis, cirrhosis, hepatocellular adenomas and hepatocellular carcinomas. Symptoms can also include insulin insensitivity, elevated or decreased blood sugar, renal dysfunction and / or fibrosis.

[0037] As used herein, "inflammatory disease" refers to a disease or condition characterized by inflammation. Exemplary inflammatory diseases include, but are not limited to, acne, acid reflux / heartburn, age-related macular degeneration (AMD), allergies, allergic rhinitis, Alzheimer's disease, amyotrophic lateral sclerosis, anemia, appendicitis, arteritis, arthritis, asthma, atherosclerosis, autoimmune diseases, balanitis, blepharitis, bronchiolitis, bronchitis, bullous pemphigoid, burns, bursitis, cancer, cardiac arrest, myocarditis, celiac disease, cellulitis, cervicitis, cholangitis, cholecystitis, chorioamnionitis, chronic obstructive pulmonary disease (COPD), cirrhosis, colitis, congestive heart failure, Conjunctivitis, cyclophosphamide-induced cystitis, cystic fibrosis, cystitis, common cold, lacrimal gland inflammation, dementia, dermatitis, dermatomyositis, diabetes, diabetic neuropathy, diabetic retinopathy, diabetic nephropathy, diabetic ulcer, digestive system diseases, eczema, emphysema, encephalitis, endocarditis, endometritis, enteritis, enterocolitis, epicondylitis, epididymitis, fasciitis, fibromyalgia, fibrosis, fibrositis, gastritis, gastroenteritis, gingivitis, glomerulonephritis, glossitis, heart disease, heart valve dysfunction, hepatitis, suppurative hidradenitis, Huntington's disease, hyperlipidemic pancreatitis, hypertension, Ileitis, infection, inflammatory bowel disease, inflammatory cardiomegaly, inflammatory neuropathy, insulin resistance, interstitial cystitis, interstitial nephritis, iritis, ischemia, ischemic heart disease, keratitis, keratoconjunctivitis, laryngitis, lupus nephritis, mastitis, mastoiditis, meningitis, metabolic syndrome (syndrome X), migraine, multiple sclerosis, myelitis, myocarditis, myositis, nephritis, nonalcoholic steatohepatitis, obesity, omphalitis, oophoritis, orchitis, osteochondritis, osteopenia, osteomyelitis, osteoporosis, osteitis, otitis, pancreatitis, Parkinson's disease, mumps, pelvic inflammatory disease, common Pemphigus, pericarditis, peritonitis, pharyngitis, phlebitis, pleurisy, pneumonia, polycystic nephritis, proctitis, prostatitis, psoriasis, pulpitis, pyelonephritis, portal vein inflammation, renal failure, reperfusion injury, retinitis, rheumatic fever, rhinitis, salpingitis, sarcoidosis, sialadenitis, sinusitis, spastic colon, stenosis, stomatitis, stroke, surgical complications, synovitis, tendinitis, tendinosis, tenosynovitis, thrombophlebitis, tonsillitis, trauma, traumatic brain injury, transplant rejection, bladder trigone inflammation, tuberculosis, tumor, urethritis, urticaria, uveitis, vaginitis, vasculitis and vulvitis. Inflammation referred to herein can be assessed by measuring or determining the presence or level of one or more biomarkers. Biomarkers of the presence of inflammation include, but are not limited to, expression of TNF, CARD15, IL4R, IL23R, CTLA4, ANXA1, ANXA2, LGALS3, and / or PTPN22 genes, or any combination or product thereof.

[0038] The term "atherosclerosis" refers to a condition characterized by irregularly distributed lipid deposits in the intima of large and medium-sized arteries, wherein such deposits cause fibrosis and calcification. Atherosclerosis increases the risk of angina, stroke, heart attack or other cardiac or cardiovascular conditions.

[0039] "Subject in need thereof" means a subject identified as being in need of treatment or therapy.

[0040] The therapeutic effect alleviates one or more symptoms of the disease or condition to some extent, and includes curing the disease or condition. "Cure" means that the symptoms of active disease are eliminated. However, even after a cure is achieved (e.g., extensive tissue damage), there may be certain long-term or permanent effects of the disease.

[0041] As used herein, "treat," "treatment," or "treating" refers to the administration of a pharmaceutical composition for preventive and / or therapeutic purposes. The term "prophylactic treatment" refers to treating a patient who does not yet have the relevant disease or condition, but is susceptible to or at risk for a particular disease or condition, whereby the treatment reduces the likelihood that the patient will develop the disease or condition. The term "therapeutic treatment" refers to administering a treatment to a patient who already has a disease or condition.

[0042] "Preventing" or "prevention" means delaying or arresting the onset, development or progression of a condition or disease for a period of time, including weeks, months or years.

[0043] "Improvement" means reducing the severity of at least one indicator of a condition or disease. In certain embodiments, improvement includes a delay or slowing of the progression of one or more indicators of a condition or disease. The severity of an indicator can be determined by subjective or objective measurements known to those skilled in the art.

[0044] "Regulation" means a disturbance of function or activity. In certain embodiments, regulation means an increase in gene expression. In certain embodiments, regulation means a decrease in gene expression. In certain embodiments, regulation means an increase or decrease in the total serum level of a specific protein. In certain embodiments, regulation means an increase or decrease in the free serum level of a specific protein. In certain embodiments, regulation means an increase or decrease in the total serum level of a specific non-protein factor. In certain embodiments, regulation means an increase or decrease in the free serum level of a specific non-protein factor. In certain embodiments, regulation means an increase or decrease in the total bioavailability of a specific protein. In certain embodiments, regulation means an increase or decrease in the total bioavailability of a specific non-protein factor.

[0045] "Administering" means providing an agent or composition to a subject, and includes, but is not limited to, administration by a medical professional and self-administration.

[0046] The term "agent" includes any substance, molecule, element, compound, entity or combination thereof. It includes, but is not limited to, for example, proteins, polypeptides, peptides or mimetics, small organic molecules, polysaccharides, polynucleotides, etc. It can be a natural product, a synthetic compound or a chemical compound or a combination of two or more substances.

[0047] "Pharmaceutical agent" means a substance that provides a therapeutic effect when administered to a subject.

[0048] "Pharmaceutical composition" means a mixture of substances, including medicaments, suitable for administration to an individual. For example, a pharmaceutical composition may comprise a modified oligonucleotide and a sterile aqueous solution.

[0049] The term "pharmaceutically acceptable salt" refers to a salt that retains the biological effectiveness and properties of the compound to which it is associated and is not biologically or otherwise undesirable. In many cases, the compounds herein are capable of forming acid and / or base salts due to the presence of phenol and / or phosphonate groups or groups similar thereto. Those of ordinary skill in the art will appreciate that the protonation state of any or all of these compounds may vary with the pH and ionic characteristics of the surrounding solution, so the disclosure contemplates a variety of charge states for each compound. Pharmaceutically acceptable acid addition salts may be formed with inorganic and organic acids. Inorganic acids from which salts may be derived include, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, etc. Organic acids from which salts may be derived include, for example, acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, etc. Pharmaceutically acceptable base addition salts can be formed with inorganic and organic bases. Inorganic bases from which salts can be derived include, for example, sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum, and the like; ammonium, potassium, sodium, calcium, and magnesium salts are particularly preferred. Organic bases from which salts can be derived include, for example, primary, secondary, and tertiary amines, substituted amines, including naturally occurring substituted amines, cyclic amines, basic ion exchange resins, and the like, particularly, for example, isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, and ethanolamine. Many such salts are known in the art, as described in WO87 / 05297, Johnston et al., published September 11, 1987 (incorporated herein by reference in its entirety). Pharmaceutical composition

[0050] The compounds useful as described above can be formulated into pharmaceutical compositions for treating the conditions described herein. In some embodiments, pharmaceutical compositions comprising Compound 1 can be formulated for oral administration. In some specific embodiments, pharmaceutical compositions comprising Compound 1 can be formulated into tablets. Some embodiments of the pharmaceutical compositions described herein comprise: (a) a safe and therapeutically effective amount of Compound 1 or a pharmaceutically acceptable salt thereof; and (b) a pharmaceutically acceptable carrier, diluent, excipient, or a combination thereof.

[0051] The compositions described herein are preferably provided in unit dosage form. As used herein, a "unit dosage form" is a composition in a single dose according to good medical practice, which contains an amount of a compound suitable for administration to a subject. However, the preparation of a single or unit dosage form does not mean that the dosage form is administered once a day or once per course of treatment. A unit dosage form may comprise a single daily dose or a partial sub-dose, wherein several unit dosage forms are administered over the course of a day in order to complete the daily dose. According to the present disclosure, a unit dosage form may be administered more or less than once a day, and may be administered more than once during the course of treatment.

[0052] The actual unit dosage of Compound 1 described herein depends on the specific compound and the condition to be treated. In some embodiments, the dosage can be from about 0.01 mg / kg to about 120 mg / kg or more body weight, from about 0.05 mg / kg or less to about 70 mg / kg, from about 0.1 mg / kg to about 50 mg / kg body weight, from about 1.0 mg / kg to about 10 mg / kg body weight, from about 5.0 mg / kg to about 10 mg / kg body weight, or from about 10.0 mg / kg to about 20.0 mg / kg body weight. In some embodiments, the dosage can be less than 100mg / kg, 90mg / kg, 80mg / kg, 70mg / kg, 60mg / kg, 50mg / kg, 40mg / kg, 30mg / kg, 25mg / kg, 20mg / kg, 10mg / kg, 7.5mg / kg, 6mg / kg, 5mg / kg, 4mg / kg, 3mg / kg, 2.5mg / kg, 1mg / kg, 0.5mg / kg, 0.1mg / kg, 0.05mg / kg or 0.005mg / kg body weight. In some embodiments, the actual unit dose is 0.05mg / kg, 0.07mg / kg, 0.1mg / kg, 0.3mg / kg, 1.0mg / kg, 3.0mg / kg, 5.0mg / kg, 10.0mg / kg or 25.0mg / kg body weight. Thus, for administration to a 70 kg person, the dosage range will be about 0.1 mg to 70 mg, about 1 mg to about 50 mg, about 0.5 mg to about 10 mg, about 1 mg to about 10 mg, about 2.5 mg to about 30 mg, about 35 mg or less to about 700 mg or more, about 7 mg to about 600 mg, about 10 mg to about 500 mg, or about 20 mg to about 300 mg, or about 200 mg to about 2000 mg. In some embodiments, the actual unit dose is 0.1 mg. In some embodiments, the actual unit dose is 0.5 mg. In some embodiments, the actual unit dose is 1 mg. In some embodiments, the actual unit dose is 1.5 mg. In some embodiments, the actual unit dose is 2 mg. In some embodiments, the actual unit dose is 2.5 mg. In some embodiments, the actual unit dose is 3 mg. In some embodiments, the actual unit dose is 3.5 mg. In some embodiments, the actual unit dose is 4 mg. In some embodiments, the actual unit dose is 4.5 mg. In some embodiments, the actual unit dose is 5 mg. In some embodiments, the actual unit dose is 10 mg. In some embodiments, the actual unit dose is 20 mg. In some embodiments, the actual unit dose is 25 mg. In some embodiments, the actual unit dose is 250 mg or less. In some embodiments, the actual unit dose is 100 mg or less.In some embodiments, the actual unit dose is 70 mg or less.

[0053] In some embodiments, Compound 1 is administered in an amount ranging from about 1 mg / m 2 Up to 50 mg / m 2In some embodiments, Compound 1 is administered in a dose ranging from about 1-2, 1-3, 1-4, 1-5, 1-6, 1-7, 1-8, 1-9, 1-10, 1-11, 1-12, 1-13, 1-13.75, 1-14, 1-15, 1-16, 1-17, 1-18, 1-19, 1-20, 1-22.5, 1-25, 1-27.5, 1-30, 1.5-2, 1.5-3, 1.5-4, 1.5-5, 1.5-6, 1.5-7, 1.5-8, 1.5-9, 1.5-10, 1.5-11, 1.5-12, 1.5-13, 1.5-13.75, 1.5-14, 1.5-15, 1.5- 16, 1.5-17, 1.5-18, 1.5-19, 1.5-20, 1.5-22.5, 1.5-25, 1.5-27.5, 1.5-30, 2.5-2, 2.5-3, 2.5-4, 2.5-5, 2.5-6, 2.5-7, 2.5-8, 2.5-9, 2.5-10, 2.5-11, 2.5-12, 2.5-13, 2.5-13.75, 2.5-14, 2.5-15, 2.5-16, 2.5-17, 2.5-18, 2.5-19, 2.5-20, 2.5-22.5, 2.5-25, 2.5-27.5, 2.5-30, 2.5-7.5, 3-4, 3-5, 3-6, 3-7, 3-8, 3-9, 3-10, 3-11, 3-12, 3-13, 3-13.75, 3-14, 3-15, 3-16, 3-17, 3-18, 3-19, 3-20, 3-22.5, 3-25, 3-27.5, 3-30, 3.5-6.5, 3.5-13.75, 3.5-15, 2.5-17.5, 4-5, 4-6, 4-7, 4-8, 4-9, 4-10, 4-11, 4-12, 4-13, 4-13.75, 4-14, 4-15, 4-16, 4-17, 4-18, 4-19, 4-20, 4-22.5, 4-25, 4-27. 5, 4-30, 5-6, 5-7, 5-8, 5-9, 5-10, 5-11, 5-12, 5-13, 5-13.75, 5-14, 5-15, 5-16, 5-17, 5-18, 5-19, 5-20, 5-22.5, 5-25, 5-27.5, 5-30, 6-7, 6-8, 6-9, 6-10, 6-11, 6-12, 6-13, 6-13.75, 6-14, 6-15, 6-16, 6-17, 6-18, 6-19, 6-20, 6-22.5, 6-25, 6-27.5, 6-30, 7-8, 7-9, 7-10, 7-11, 7-12, 7-13, 7-13.75, 7-14, 7-15, 7-16, 7-17, 7-18, 7-19, 7-20, 7-22.5, 7-25, 7-27.5, 7-30, 7.5-12.5, 7.5-13.5, 7.5-15, 8-9, 8-10, 8-11, 8-12, 8-13, 8-13.75, 8-14, 8 -15, 8-16, 8-17, 8-18, 8-19, 8-20, 8-22.5, 8-25, 8-27.5, 8-30, 9-10, 9-11, 9-12, 9-13, 9-13.75, 9-14, 9-15, 9-16, 9-17, 9-18, 9-19, 9-20, 9-22.5, 9-2 5, 9-27.5, 9-30, 10-11, 10-12, 10-13, 10-13.75, 10-14, 10-15, 10-16, 10-17, 10-18, 10-19, 10-20, 10-22.5, 10-25, 10-27.5, 10-30, 11.5-15.5, 12.5 -14.5, 7.5-22.5, 8.5-32.5, 9.5-15.5, 15.5-24.5, 5-35, 17.5-22.5, 22.5-32.5, 25-35, 25.5-24.5, 27.5-32.5, 2-20, 2.5-22.5, or 9.5-21.5 body surface area. In some embodiments, Compound 1 is administered at about 0.5 mg / m. 2 , 1mg / m 2 , 1.5mg / m 2 , 2mg / m 2 , 2.5mg / m 2 , 3mg / m 2 , 3.5mg / m 2 , 4mg / m 2 4.5mg / m 2 , 5mg / m 2 , 5.5mg / m 2 , 6mg / m 2 , 6.5mg / m 2 , 7mg / m 2 , 7.5mg / m 2 , 8mg / m 2 , 8.5mg / m 2 , 9mg / m 2 , 9.5mg / m 2 , 10mg / m 2 , 10.5mg / m 2 , 11mg / m 2 , 11.5mg / m 2 , 12mg / m 2、12.5mg / m 2 、13mg / m 2 、13.5mg / m 2 、14mg / m 2 、14.5mg / m 2 、15mg / m 2 、15.5mg / m 2 、16mg / m 2 、16.5mg / m 2 、17mg / m 2 、17.5mg / m 2 、18mg / m 2 、18.5mg / m 2 、19mg / m 2 、19.5mg / m 2 、20mg / m 2 、20.5mg / m 2 、21mg / m 2 、21.5mg / m 2 、22mg / m 2 、22.5mg / m 2 、23mg / m 2 、23.5mg / m 2 、24mg / m 2 、24.5mg / m 2 、25mg / m 2 、25.5mg / m 2 、26mg / m 2 、26.5mg / m 2 、27mg / m 2 、27.5mg / m 2 、28mg / m 2 、28.5mg / m 2 、29mg / m 2 、29.5mg / m 2 、30mg / m 2 、30.5mg / m 2 、31mg / m 2 、32mg / m 2 、33mg / m 2 、34mg / m 2 、35mg / m 2 、36mg / m 2 、37mg / m 2 、38mg / m 2 、39mg / m 2 、40mg / m 2In some embodiments, Compound 1 is administered at a dose of less than about 0.5 mg / m 2 , 1mg / m 2 , 1.5mg / m 2 , 2mg / m 2 , 2.5mg / m 2 , 3mg / m 2 , 3.5mg / m 2 , 4mg / m 2 4.5mg / m 2 , 5mg / m 2 , 5.5mg / m 2 , 6mg / m 2 , 6.5mg / m 2 , 7mg / m 2 , 7.5mg / m 2 , 8mg / m 2 , 8.5mg / m 2 , 9mg / m 2 , 9.5mg / m 2 , 10mg / m 2 , 10.5mg / m 2 , 11mg / m 2 , 11.5mg / m 2 , 12mg / m 2 , 12.5mg / m 2 , 13mg / m 2 , 13.5mg / m 2 , 14mg / m 2 , 14.5mg / m 2 , 15mg / m 2 , 15.5mg / m 2 , 16mg / m 2 , 16.5mg / m 2 , 17mg / m 2 , 17.5mg / m 2 , 18mg / m 2 , 18.5mg / m 2 , 19mg / m 2 , 19.5mg / m 2 , 20mg / m 2 , 20.5mg / m 2 , 21mg / m 2 , 21.5mg / m 2 , 22mg / m 2 , 22.5mg / m 2 , 23mg / m 2 , 23.5mg / m 2, 24mg / m 2 , 24.5mg / m 2 , 25mg / m 2 , 25.5mg / m 2 , 26mg / m 2 , 26.5mg / m 2 , 27mg / m 2 , 27.5mg / m 2 , 28mg / m 2 , 28.5mg / m 2 , 29mg / m 2 , 29.5mg / m 2 , 30mg / m 2 , 30.5mg / m 2 , 31mg / m 2 , 32mg / m 2 , 33mg / m 2 , 34mg / m 2 , 35mg / m 2 , 36mg / m 2 , 37mg / m 2 , 38mg / m 2 , 39mg / m 2 , 40mg / m 2 In some embodiments, Compound 1 is administered at a dose greater than about 0.5 mg / m 2 , 1mg / m 2 , 1.5mg / m 2 , 2mg / m 2 , 2.5mg / m 2 , 3mg / m 2 , 3.5mg / m 2 , 4mg / m 2 4.5mg / m 2 , 5mg / m 2 , 5.5mg / m 2 , 6mg / m 2 , 6.5mg / m 2 , 7mg / m 2 , 7.5mg / m 2 , 8mg / m 2 , 8.5mg / m 2 , 9mg / m 2 , 9.5mg / m 2 , 10mg / m 2 , 10.5mg / m 2 , 11mg / m 2 , 11.5mg / m 2 , 12mg / m2 、12.5mg / m 2 、13mg / m 2 、13.5mg / m 2 、14mg / m 2 、14.5mg / m 2 、15mg / m 2 、15.5mg / m 2 、16mg / m 2 、16.5mg / m 2 、17mg / m 2 、17.5mg / m 2 、18mg / m 2 、18.5mg / m 2 、19mg / m 2 、19.5mg / m 2 、20mg / m 2 、20.5mg / m 2 、21mg / m 2 、21.5mg / m 2 、22mg / m 2 、22.5mg / m 2 、23mg / m 2 、23.5mg / m 2 、24mg / m 2 、24.5mg / m 2 、25mg / m 2 、25.5mg / m 2 、26mg / m 2 、26.5mg / m 2 、27mg / m 2 、27.5mg / m 2 、28mg / m 2 、28.5mg / m 2 、29mg / m 2 、29.5mg / m 2 、30mg / m 2 、30.5mg / m 2 、31mg / m 2 、32mg / m 2 、33mg / m 2 、34mg / m 2 、35mg / m 2 、36mg / m 2 、37mg / m 2 、38mg / m 2 、39mg / m 2 、40mg / m 2 、41mg / m2 42mg / m 2 43mg / m 2 44mg / m 2 45mg / m 2 46mg / m 2 47mg / m 2 48mg / m 2 , 49mg / m 2 , 50mg / m 2 Dosage administration by body surface area.

[0054] In some embodiments, the Compound 1 dosage is about 0.1 mg to 100 mg, 0.1 mg to 50 mg, 0.1 mg to 20 mg, 0.1 mg to 10 mg, 0.5 mg to 100 mg, 0.5 mg to 50 mg, 0.5 mg to 20 mg, 0.5 mg to 10 mg, 1 mg to 100 mg, 1 mg to 50 mg, 1 mg to 20 mg, 1 mg to 10 mg, 2.5 mg to 50 mg, 2.5 mg to 20 mg, 2.5 mg to 10 mg, or about 2.5 mg to 5 mg. In some embodiments, the TR-β agonist compound dose is about 5 mg to 300 mg, 5 mg to 200 mg, 7.5 mg to 200 mg, 10 mg to 100 mg, 15 mg to 100 mg, 20 mg to 100 mg, 30 mg to 100 mg, 40 mg to 100 mg, 10 mg to 80 mg, 15 mg to 80 mg, 20 mg to 80 mg, 30 mg to 80 mg, 40 mg to 80 mg, 10 mg to 60 mg, 15 mg to 60 mg, 20 mg to 60 mg, 30 mg to 60 mg, or about 40 mg to 60 mg. In some embodiments, the amount of Compound 1 administered is about 20 mg to 60 mg, 27 mg to 60 mg, 20 mg to 45 mg, or 27 mg to 45 mg. In some embodiments, the amount of Compound 1 administered is about 5 mg to 7.5 mg, 5 mg to 9 mg, 5 mg to 10 mg, 5 mg to 12 mg, 5 mg to 14 mg, 5 mg to 15 mg, 5 mg to 16 mg, 5 mg to 18 mg, 5 mg to 20 mg, 5 mg to 22 mg, 5 mg to 24 mg, 5 mg to 26 mg, 5 mg to 28 mg, 5 mg to 30 mg, 5 mg to 32 mg, 5 mg to 34 mg, 5 mg to 36 mg, 5 mg to 38 mg, 5 mg to 40 mg, 5 mg to 42 mg, 5 mg to 44 mg, 5 mg to 46 mg, 5 mg to 48 mg, 5 mg to 50 mg, 5 mg to 52 mg, 5 mg to 54 mg, 5 mg to 56 mg, 5 mg to 58 mg , 5mg to 60mg, 7mg to 7.7mg, 7mg to 9mg, 7mg to 10mg, 7mg to 12mg, 7mg to 14mg, 7mg to 15mg, 7mg to 16mg, 7mg to 18mg, 7mg to 20mg, 7mg to 22mg, 7mg to 24mg, 7mg to 26mg, 7mg to 28mg, 7mg to 30mg, 7mg to 32mg, 7mg to 34mg, 7mg to 36mg, 7mg to 38mg, 7mg to 40mg, 7mg to 42mg, 7mg to 44mg, 7mg to 46mg, 7mg to 48mg, 7mg to 50mg, 7mg to 52mg, 7mg to 54mg, 7mg to 56mg, 7mg to 58mg, 7mg to 60mg,9mg to 10mg, 9mg to 12mg, 9mg to 14mg, 9mg to 15mg, 9mg to 16mg, 9mg to 18mg, 9mg to 20mg, 9mg to 22mg, 9mg to 24mg, 9mg to 26mg, 9mg to 28mg, 9mg to 30mg, 9mg to 32mg, 9mg to 34mg, 9mg to 36mg, 9mg to 38mg, 9mg to 40mg, 9mg to 42mg, 9mg to 44mg, 9mg to 46mg, 9mg to 48mg, 9mg to 50mg, 9mg to 52mg, 9mg to 54mg, 9mg to 56mg, 9mg to 58mg, 9mg to 60mg, 10mg to 12mg, 10mg to 14mg, 10mg to 15mg, 10mg to 16mg, 10mg to 18mg, 10mg to 20mg, 10mg to 22mg, 10mg to 24mg, 10mg to 26mg, 10mg to 28mg, 10mg to 30mg, 10mg to 32mg, 10mg to 34mg, 10mg to 36mg, 10mg to 38mg, 10mg to 40mg, 10mg to 42mg, 10mg to 44mg, 10mg to 46mg, 10mg to 48mg, 10mg to 50mg, 10mg to 52mg, 10mg to 54mg, 10mg to 56mg, 10mg to 58mg, 10mg to 12mg to 60mg, 12mg to 14mg, 12mg to 15mg, 12mg to 16mg, 12mg to 18mg, 12mg to 20mg, 12mg to 22mg, 12mg to 24mg, 12mg to 26mg, 12mg to 28mg, 12mg to 30mg, 12mg to 32mg, 12mg to 34mg, 12mg to 36mg, 12mg to 38mg, 12mg to 40mg, 12mg to 42mg, 12mg to 44mg, 12mg to 46mg, 12mg to 48mg, 12mg to 50mg, 12mg to 52mg, 12mg to 54mg, 12mg to 56mg, 12mg to 58mg, 1 2mg to 60mg, 15mg to 16mg, 15mg to 18mg, 15mg to 20mg, 15mg to 22mg, 15mg to 24mg, 15mg to 26mg, 15mg to 28mg, 15mg to 30mg, 15mg to 32mg, 15mg to 34mg, 15mg to 36mg, 15mg to 38mg, 15mg to 40mg, 15mg to 42mg, 15mg to 44mg, 15mg to 46mg, 15mg to 48mg, 15mg to 50mg, 15mg to 52mg, 15mg to 54mg, 15mg to 56mg, 15mg to 58mg, 15mg to 60mg, 17mg to 18mg,17mg to 20mg, 17mg to 22mg, 17mg to 24mg, 17mg to 26mg, 17mg to 28mg, 17mg to 30mg, 17mg to 32mg, 17mg to 34mg, 17mg to 36mg, 17mg to 38mg, 17mg to 40mg, 17mg to 42mg, 17mg to 44mg, 17mg to 46mg, 17mg to 48mg, 17mg to 50mg, 17mg to 52mg, 17mg to 54mg, 17mg to 56mg, 17mg to 58mg, 17mg to 60mg, 20mg to 22mg, 20mg to 24mg, 20mg to 26mg, 20mg to 28mg, 20mg to 30mg, 20mg to 32mg, 20mg to 34mg, 20mg to 36mg, 20mg to 38mg, 20mg to 40mg, 20mg to 42mg, 20mg to 44mg, 20mg to 46mg, 20mg to 48mg, 20mg to 50mg, 20mg to 52mg, 20mg to 54mg, 20mg to 56mg, 20mg to 58mg, 20mg to 60mg, 22mg to 24mg, 22mg to 26mg, 22mg to 28mg, 22mg to 30mg, 22mg to 32mg, 22mg to 34mg, 22mg to 36mg, 22mg to 38mg, 22mg to 40mg, 22mg to 42mg, 22mg to 44mg, 22mg to 46mg, 22mg to 48mg, 22mg to 50mg, 22mg to 52mg, 22mg to 54mg, 22mg to 56mg, 22mg to 58mg, 22mg to 60mg, 25mg to 26mg, 25mg to 28mg, 25mg to 30mg, 25mg to 32mg, 25mg to 34mg, 25mg to 36mg, 25mg to 38mg, 25mg to 40mg, 25mg to 42mg, 25mg to 44mg, 25mg to 46mg, 25mg to 48mg, 25mg to 50mg, 25mg to 52mg, 25mg to 54mg, 25mg to 56mg, 25mg to 58mg, 25mg to 60mg, 27mg to 28mg, 27mg to 30mg, 27mg to 32mg, 27mg to 34mg, 27mg to 36mg, 27mg to 38mg, 27mg to 40mg, 27mg to 42mg, 27mg to 44mg, 27mg to 46mg, 27mg to 48mg, 27mg to 50mg, 27mg to 52mg, 27mg to 54mg, 27mg to 56mg, 27mg to 58mg, 27mg to 60mg, 30mg to 32mg, 30mg to 34mg, 30mg to 36mg, 30mg to 38mg, 30mg to 40mg,30mg to 42mg, 30mg to 44mg, 30mg to 46mg, 30mg to 48mg, 30mg to 50mg, 30mg to 52mg, 30mg to 54mg, 30mg to 56mg, 30mg to 58mg, 30mg to 60mg, 33mg to 34mg, 33mg to 36mg, 33mg to 38mg, 33mg to 40mg, 33mg to 42mg, 33mg to 44mg, 33mg to 46mg, 33mg to 48mg, 33mg to 50mg, 33mg to 52mg, 33mg to 54mg, 33mg to 56mg, 33mg to 58mg, 33mg to 60mg, 36mg to 38mg, 36mg to 40mg, 36mg to 42mg, 36mg to 44mg, 36mg to 46mg, 36mg to 48mg, 36mg to 50mg, 36mg to 52mg, 36mg to 54mg, 36mg to 56mg, 36mg to 58mg, 36mg to 60mg, 40mg to 42mg, 40mg to 44mg, 40mg to 46mg, 40mg to 48mg, 40mg to 50mg, 40mg to 52mg, 40mg to 54mg, 40mg to 56mg, 40mg to 58mg, 40mg to 60mg, 43mg to 46mg, 43mg to 48mg, 43mg to 50mg, 43mg to 52mg, 43mg to 54mg, 43mg to 56mg, 43mg to 58mg, 42mg to 60mg, 45mg to 48mg, 45mg to 50mg, 45mg to 52mg, 45mg to 54mg, 45mg to 56mg, 45mg to 58mg, 45mg to 60mg, 48mg to 50mg, 48mg to 52mg, 48mg to 54mg, 48mg to 56mg, 48mg to 58mg, 48mg to 60mg, 50mg to 52mg, 50mg to 54mg, 50mg to 56mg, 50mg to 58mg, 50mg to 60mg, 52mg to 54mg, 52mg to 56mg, 52mg to 58mg or 52mg to 60mg. In some embodiments, the dose of Compound 1 is greater than about 5 mg, about 10 mg, about 12.5 mg, about 13.5 mg, about 15 mg, about 17.5 mg, about 20 mg, about 22.5 mg, about 25 mg, about 27 mg, about 30 mg, about 40 mg, about 50 mg, about 60 mg, about 70 mg, about 80 mg, about 90 mg, about 100 mg, about 125 mg, about 150 mg, or about 200 mg. In some embodiments, the dose of Compound 1 is less than about 5 mg, about 10 mg, about 12.5 mg, about 13.5 mg, about 15 mg, about 17.5 mg, about 20 mg, about 22.5 mg, about 25 mg, about 27 mg, about 30 mg, about 40 mg, about 50 mg, about 60 mg, about 70 mg, about 80 mg, about 90 mg, about 100 mg, about 125 mg, about 150 mg, or about 200 mg.About 30 mg, about 40 mg, about 50 mg, about 60 mg, about 70 mg, about 80 mg, about 90 mg, about 100 mg, about 125 mg, about 150 mg, or about 200 mg. In some embodiments, the dose of Compound 1 is about 5 mg, about 10 mg, about 12.5 mg, about 13.5 mg, about 15 mg, about 17.5 mg, about 20 mg, about 22.5 mg, about 25 mg, about 27 mg, about 30 mg, about 40 mg, about 50 mg, about 60 mg, about 70 mg, about 80 mg, about 90 mg, about 100 mg, about 125 mg, about 150 mg, about 200 mg, about 225 mg, about 250 mg, about 275 mg, or about 300 mg. Tablet formulation

[0055] Compound 1 can be combined with one or more polymers and then further formulated into a desired dosage form. In some embodiments, compound 1 is in the form of a spray dried dispersion (SDD). In other embodiments, compound 1 is in the form of a hot melt extrudate. In some embodiments, the dosage form is an oral dosage form. In some specific embodiments, the oral dosage form is a tablet. In other embodiments, the oral dosage form is a capsule.

[0056] In some embodiments, the polymer used to prepare the spray-dried dispersion containing Compound 1 can be selected from one or more of the following: polyvinyl pyrrolidone (PVP), polyvinyl pyrrolidone-vinyl acetate copolymer (PVP-VA), polyvinyl alcohol (PVA), polyacrylic acid (PAA), poly (ethylene oxide) (PEO), hydroxypropyl cellulose (HPC), hydroxypropyl methylcellulose (HPMC), copovidone, poloxamer 407, hydroxypropyl methylcellulose acetate succinate (HPMCAS), and polyacrylates. In some embodiments, the polymer may be PVP. In some embodiments, the polymer may be PVP-VA. In other embodiments, the polymer may be HPMCAS. In other embodiments, the polymer may be HPMC. In some embodiments, the polymer may be In some embodiments, the polymer used to prepare the spray-dried dispersion of Compound 1 can be a combination of PVP-VA and Poloxamer 407.

[0057] Spray-dried dispersions of compound 1 and one or more polymers can be prepared by combining compound 1 and the polymer in a suitable solvent and then spraying the feed into a hot drying medium to remove the solvent. Preparing a spray-dried dispersion (SDD) of compound 1 and one or more polymers can increase the water solubility (and therefore bioavailability) of compound 1, and can increase the stability of compound 1 so that it can be stored under normal conditions.

[0058] In some embodiments, the mass ratio of Compound 1 to polymer in SDD is about 1:10 to about 10:1. For example, in some embodiments, the mass ratio of Compound 1 to polymer in SDD is about 1:1, 1.5:1, 2:1, 2.5:1, 3:1, 3.5:1, 4:1, 4.5:1, or 5:1. In some embodiments, the mass ratio of Compound 1 to polymer in SDD can range from about 1:1 to 5:1, 1.5:1 to 5:1, 2:1 to 4:1, 2.5:1 to 3.5:1, or 3:1 to 5:1. In some embodiments, the mass ratio of Compound 1 to polymer in SDD can range from about 1:1 to 1:5, 1:1 to 1:4, 1:1 to 1:3, or 1:2 to 1:4. In some embodiments, the mass ratio of Compound 1 to polymer in SDD can be about 1:3.

[0059] Compound 1 can be formulated into tablets for oral administration to objects in need. In some embodiments, the compound 1 in the tablet can be present with about 5 weight %, 6 weight %, 7 weight %, 8 weight %, 9 weight %, 10 weight %, 11 weight %, 12 weight %, 13 weight %, 14 weight %, 15 weight %, 16 weight %, 17 weight %, 18 weight %, 19 weight %, 20 weight %, 21 weight %, 22 weight %, 23 weight %, 24 weight % or 25 weight % of the tablet or the scope defined by any two of the above amounts. For example, in some embodiments, the compound 1 in the tablet can be present with about 5 weight % to 25 weight %, 10 weight % to 20 weight %, 5 weight % to 15 weight % or 10 weight % to 15 weight %.

[0060] The tablet formulations of compound 1 described herein may further include a ductile filler. In some embodiments, the ductile filler in the tablet may be present at about 30% by weight, 35% by weight, 40% by weight, 45% by weight, 50% by weight, 55% by weight, 60% by weight, 65% by weight, or 70% by weight of the tablet, or a range defined by any two of the above amounts. For example, in some embodiments, the ductile filler in the tablet may be present at about 30% by weight to 70% by weight, 40% by weight to 60% by weight, 45% by weight to 55% by weight, or 50% by weight to 55% by weight. In some embodiments, the ductile filler may be microcrystalline cellulose. In other embodiments, the ductile filler may include silicified microcrystalline cellulose.

[0061] The tablet formulation of compound 1 described herein may further include a brittle filler. In some embodiments, the brittle filler in the tablet may be present in about 10% by weight, 15% by weight, 20% by weight, 25% by weight, 30% by weight, 35% by weight or 40% by weight of the tablet or in a range defined by any two of the above amounts. For example, in some embodiments, the brittle filler in the tablet may be present in about 10% by weight to 40% by weight, 10% by weight to 30% by weight, 15% by weight to 30% by weight or 20% by weight to 30% by weight. In some embodiments, the brittle filler may be lactose monohydrate, spray-dried lactose, anhydrous lactose, lactose monohydrate, anhydrous lactose, mannitol or a combination thereof. In some specific embodiments, the brittle filler may be lactose monohydrate. In other specific embodiments, the brittle filler may be mannitol. In other specific embodiments, the brittle filler may be anhydrous lactose.

[0062] The tablet formulation of compound 1 described herein may further include a disintegrant. In some embodiments, the disintegrant in the tablet may be present in a range of about 5% by weight, 6% by weight, 7% by weight, 8% by weight, 9% by weight, 10% by weight, 11% by weight, 12% by weight, 13% by weight, 14% by weight, 15% by weight, 16% by weight, 17% by weight, 18% by weight, 19% by weight, or 20% by weight of the tablet, or defined by any two of the above amounts. For example, in some embodiments, the disintegrant in the tablet may be present in a range of about 5% by weight to 20% by weight, 5% by weight to 15% by weight, 10% by weight to 15% by weight, or 10% by weight to 20% by weight. In some embodiments, the disintegrant may be carboxymethylcellulose calcium, sodium carboxymethyl starch, cross-linked sodium carboxymethyl cellulose, starch, pregelatinized starch, sodium starch glycolate, cross-linked polyvinyl pyrrolidone cross-polyvidone, hydroxypropyl cellulose, magnesium aluminum silicate, potassium polycrilin, or any combination thereof. In some specific embodiments, the disintegrant may be cross-linked sodium carboxymethyl cellulose. In other embodiments, the disintegrant may be crospovidone.

[0063] The tablet formulation of compound 1 described herein may further include a glidant. In some embodiments, the glidant in the tablet may be present in a range of about 0.1% by weight, 0.2% by weight, 0.3% by weight, 0.4% by weight, 0.5% by weight, 0.6% by weight, 0.7% by weight, 0.8% by weight, 0.9% by weight, 1.0% by weight, 1.1% by weight, 1.2% by weight, 1.3% by weight, 1.4% by weight, 1.5% by weight, 1.6% by weight, 1.7% by weight, 1.8% by weight, 1.9% by weight or 2.0% by weight of the tablet or defined by any two of the above amounts. For example, in some embodiments, the glidant in the tablet may be present in a range of about 0.1% by weight to 2.0% by weight, 0.3% by weight to 2.0% by weight, 0.1% by weight to 1.0% by weight or 0.5% by weight to 1.0% by weight. In some embodiments, the glidant may be silicon dioxide, starch, talc or any combination thereof. In some embodiments, the glidant can be silicon dioxide.

[0064] The tablet formulation of compound 1 described herein may further include a lubricant. In some embodiments, the lubricant in the tablet may be present in an amount of about 0.1% by weight, 0.2% by weight, 0.3% by weight, 0.4% by weight, 0.5% by weight, 0.6% by weight, 0.7% by weight, 0.8% by weight, 0.9% by weight, 1.0% by weight, 1.1% by weight, 1.2% by weight, 1.3% by weight, 1.4% by weight, 1.5% by weight, 1.6% by weight, 1.7% by weight, 1.8% by weight, 1.9% by weight or 2.0% by weight of the tablet or in a range defined by any two of the above amounts. For example, in some embodiments, the lubricant in the tablet may be present in an amount of about 0.1% by weight to 2.0% by weight, 0.3% by weight to 2.0% by weight, 0.1% by weight to 1.0% by weight or 0.5% by weight to 1.0% by weight. In some embodiments, the lubricant can be stearic acid, talc, glyceryl behenate, sodium stearyl fumarate, magnesium stearate, or any combination thereof. In some specific embodiments, the lubricant can be magnesium stearate.

[0065] The tablet formulation of compound 1 described herein may include an intragranular component and an extragranular component. For example, in some embodiments, the tablet formulation may include an intragranular component and an extragranular component, wherein the intragranular component includes compound 1 and one or more polymers; a ductile filler; a brittle filler; a disintegrant; a glidant and a lubricant; and the extragranular component includes a disintegrant and a lubricant. In some embodiments, the disintegrant in the intragranular component may be the same as the disintegrant in the extragranular component. In other embodiments, the disintegrant in the intragranular component may be different from the disintegrant in the extragranular component. In some embodiments, the lubricant in the intragranular component may be the same as the lubricant in the extragranular component. In other embodiments, the lubricant in the intragranular component may be different from the lubricant in the extragranular component.

[0066] In some embodiments, a tablet formulation comprising Compound 1 as described herein comprises about 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24% or 25%, or one or more polymers within a range defined by any two of the above amounts. For example, in some embodiments, one or more polymers in the tablet may be present at about 5% to 25%, 10% to 20%, 5% to 15%, or 10% to 15%.

[0067] Unlike the current clinical formulations of compound 1, the tablet formulations comprising compound 1 described herein are stable under standard storage conditions. For example, the tablet formulations described herein are stored in high-density polyethylene bottles at 40°C or 50°C and ambient relative humidity (RH) for one month, two months, and three months, and show minimal degradation by HPLC measurement. In some embodiments, the amount of compound 1 in the tablet formulation may account for 95% by weight, 96% by weight, 97% by weight, 98% by weight, 99% by weight, or more of the original amount of compound 1 in the formulation after storage in a sealed bottle at 40°C and ambient RH for 1 month. In some embodiments, the amount of compound 1 in the tablet formulation may account for 95% by weight, 96% by weight, 97% by weight, 98% by weight, 99% by weight, or more of the original amount of compound 1 in the formulation after storage in a sealed bottle at 50°C and ambient RH for 1 month. In some embodiments, the amount of compound 1 in the tablet formulation may account for 95% by weight, 96% by weight, 97% by weight, 98% by weight, 99% by weight or more of the original amount of compound 1 in the formulation after storage in a sealed bottle at 40°C and ambient RH for 2 months. In some embodiments, the amount of compound 1 in the tablet formulation may account for 95% by weight, 96% by weight, 97% by weight, 98% by weight, 99% by weight or more of the original amount of compound 1 in the formulation after storage in a sealed bottle at 50°C and ambient RH for 2 months. In some embodiments, the amount of compound 1 in the tablet formulation may account for 95% by weight, 96% by weight, 97% by weight, 98% by weight, 99% by weight or more of the original amount of compound 1 in the formulation after storage in a sealed bottle at 40°C and ambient RH for 3 months. In some embodiments, the amount of Compound 1 in the tablet formulation may be 95%, 96%, 97%, 98%, 99% or more by weight of the original amount of Compound 1 in the formulation after storage in a sealed bottle at 50° C. and ambient RH for 3 months. Second medicine

[0068] The dosage forms of compound 1 disclosed herein can be administered in combination with one or more second agents. In some embodiments, the dosage forms of compound 1 disclosed herein can be administered in combination with one second agent. In some embodiments, the above compounds can be administered in combination with two second agents. In some embodiments, the above compounds can be administered in combination with three or more second agents.

[0069] In some embodiments, the dosage forms of compound 1 provided herein can be administered simultaneously with one or more second agents. In other embodiments, the dosage forms of compound 1 disclosed herein can be administered sequentially with one or more second agents. In some embodiments, compound 1 and the second agent are included together in the dosage forms described herein.

[0070] In one aspect, the dosage forms of Compound 1 provided herein can be administered in combination with a peroxisome proliferator-activated receptor (PPAR) modulator. PPAR modulators are pharmaceutical compounds that can be used, for example, to reduce triglyceride levels and blood glucose levels in a subject. PPAR modulators can be classified as PPARα modulators, PPARγ modulators, or PPARδ agonists. In some embodiments, a PPAR modulator can be In some embodiments, the PPAR modulator can be In some embodiments, the PPAR modulator can be In some embodiments, the PPAR modulator can be In some embodiments, the PPAR modulator may be a pharmaceutically acceptable salt or prodrug of any of the above.

[0071] In some embodiments, the dosage form of compound 1 provided herein can be administered in combination with a fibric acid derivative. A fibric acid derivative is a class of lipid-lowering drugs with the ability to reduce the lipid profile of a subject. In some embodiments, a fibric acid derivative can be fenofibrate. In some embodiments, a fibric acid derivative can be gemfibrozil. In some embodiments, a fibric acid derivative can be fenofibric acid. In some embodiments, a fibric acid derivative can be clofibrate. In some embodiments, a fibric acid derivative can be any of the above-mentioned pharmaceutically acceptable salts or prodrugs.

[0072] In some embodiments, the dosage forms of Compound 1 provided herein can be administered in combination with a bile acid receptor modulator. Bile acid receptors include, but are not limited to, FXR (farnesoid X receptor) and TGR5. In some embodiments, a bile acid receptor modulator can be In some embodiments, the bile acid receptor modulator can be In some embodiments, the bile acid receptor modulator can be In some embodiments, the bile acid receptor modulator can be (tropifexor). In some embodiments, the bile acid modulator may be a pharmaceutically acceptable salt or prodrug of any of the above.

[0073] In some embodiments, the dosage form of compound 1 provided herein can be administered in combination with a bile acid receptor modulator. In some embodiments, the bile acid receptor modulator can be selected from FXR agonists, FXR antagonists, TGR agonists, and dual FXR / TGR agonists. In some embodiments, the bile acid receptor modulator can be selected from Xu, J. Med. Chem. 2016, 59, 6553-6579 (incorporated herein by reference in its entirety), including compounds selected from the following: Where n is 2 or 3 Where R is H or F Wherein R is H or benzyl, Where R is H or methyl, Where R is H or methyl, Where Y is F or Cl, Where X is H or OMe, Where R is H or ethyl, Where R is H or OH, or a pharmaceutically acceptable salt of any of the above.

[0074] In some embodiments, the dosage forms of Compound 1 provided herein can be administered in combination with an anti-inflammatory compound. In some embodiments, the anti-inflammatory compound can be In some embodiments, the anti-inflammatory compound may be In some embodiments, the anti-inflammatory compound may be a polyclonal or monoclonal anti-LPS immunoglobulin. In some embodiments, the anti-LPS immunoglobulin may be IMM-124E. In some embodiments, the anti-inflammatory compound may be any of the pharmaceutically acceptable salts or prodrugs described above.

[0075] In some embodiments, the second agent may be an anti-fibrotic compound. In some embodiments, the anti-fibrotic compound may be In some embodiments, the anti-fibrotic compound may be In some embodiments, the anti-fibrotic compound may be a pharmaceutically acceptable salt or prodrug of any of the above.

[0076] In some embodiments, the dosage forms of Compound 1 provided herein can be administered in combination with a GLP-1 agonist. GLP-1 is a pharmaceutical compound that can be used, for example, to treat type 2 diabetes in a subject. In some embodiments, the GLP-1 agonist can be dulaglutide. In some embodiments, the GLP-1 agonist can be exenatide. In some embodiments, the GLP-1 agonist can be liraglutide. In some embodiments, the GLP-1 agonist can be albiglutide. In some embodiments, the GLP-1 agonist can be lixisenatide. In some embodiments, the GLP-1 agonist can be semaglutide. In some embodiments, the GLP-1 agonist can be glargine insulin. In some embodiments, the GLP-1 agonist is In some embodiments, the GLP-1 agonist may be a pharmaceutically acceptable salt or prodrug of any of the above.

[0077] In some embodiments, the dosage forms of Compound 1 provided herein can be administered in combination with a GLP-1 metabolic regulator. In some embodiments, the metabolic regulator can be a thyroid hormone receptor agonist. In other embodiments, the metabolic regulator can be a selective androgen receptor modulator. In some embodiments, the metabolic regulator can be a mitochondrial membrane transporter regulator. In other embodiments, the metabolic regulator can be a selective estrogen receptor modulator. In some embodiments, the metabolic regulator can be an inhibitor of stearoyl-CoA desaturase 1 (SCD1). In some embodiments, the metabolic regulator can be an inhibitor of dipeptidyl peptidase 4 (DPP-4). In some embodiments, the metabolic regulator can be an inhibitor of sodium glucose co-transporter 1 and / or 2 (SGLT1, SGLT2 or dual SGLT1 / SGLT2 inhibitor). In some embodiments, the metabolic regulator can be a recombinant fibroblast growth factor 19 (FGF19) or an engineered analog, or a recombinant fibroblast growth factor 21 (FGF21) or a pegylated variant thereof. In some embodiments, the metabolic regulator can be In some embodiments, the metabolic regulator may be In some embodiments, the metabolic regulator may be In some embodiments, the metabolic modulator may be a pharmaceutically acceptable salt or prodrug of any of the above.

[0078] In some embodiments, the dosage form of compound 1 provided herein can be administered in combination with fish oil derivatives. Fish oil contains ω-3-fatty acids, which are polyunsaturated fatty acids (PUFAs), characterized by double bonds of three atoms away from the terminal methyl group. They are widely distributed in nature and play an important role in human diet and human physiology, particularly in lipid metabolism. In some embodiments, fish oil derivatives can be ω-3-fatty acid alkyl esters. For example, fish oil derivatives can be ω-3-fatty acid methyl esters, ethyl esters, n-propyl esters or isopropyl esters. In some embodiments, fish oil derivatives can be ω-3-fatty acid triglycerides. In some embodiments, fish oil derivatives can be (5Z, 8Z, 11Z, 14Z, 17Z)-20 carbon-5,8,11,14,17-pentaenoic acid ethyl esters. In some embodiments, fish oil derivatives can be (4Z, 7Z, 10Z, 13Z, 16Z, 19Z)-22 carbon-4,7,10,13,16,19-hexaenoic acid ethyl esters. In some embodiments, the fish oil derivative may be (7Z, 10Z, 13Z, 16Z, 19Z)-docosapentaenoic acid ethyl ester. In some embodiments, the fish oil derivative may be hexadecatrienoic acid ethyl ester. In some embodiments, the fish oil derivative may be α-linolenic acid ethyl ester. In some embodiments, the fish oil derivative may be (6Z, 9Z, 12Z, 15Z)-6,9,12,15-octadecatetraenoic acid ethyl ester. In some embodiments, the fish oil derivative may be eicosatrienoic acid ethyl ester. In some embodiments, the fish oil derivative may be eicosatetraenoic acid ethyl ester. In some embodiments, the fish oil derivative may be henicosapentaenoic acid ethyl ester. In some embodiments, the fish oil derivative may be eicosapentaenoic acid ethyl ester. In some embodiments, the fish oil derivative may be henicosapentaenoic acid ethyl ester. In some embodiments, the fish oil derivative may be tetracospentaenoic acid ethyl ester. In some embodiments, the fish oil derivative may be nisinic acid ethyl ester. In some embodiments, the fish oil derivative may be any of the pharmaceutically acceptable salts or prodrugs described above. Application method

[0079] In some embodiments, the composition can be applied once, twice, three times, or four times a day. In other embodiments, the composition can be applied once, twice, or three times a week. In other embodiments, the composition is applied every other day, every three days, or every four days. In other embodiments, the composition is applied every other week, every three weeks, or every four weeks. In other embodiments, the composition is applied once a month or twice a month.

[0080] In some embodiments, an initial loading dose (loadingdose) higher than a subsequent dose (maintenance dose) is administered. The dosage form or mode of administration of the maintenance dose may be different from the dosage form or mode of administration for the loading dose. In any embodiment disclosed herein, the maintenance dose may include the administration of the unit dosage form in any dosing arrangement considered herein, including but not limited to, once a month or multiple times a month, once every two weeks or multiple times a week, once a week or multiple times a week, once a day or multiple times a day. It is expected in the present disclosure that a dosing holiday may be incorporated into the dosing period of the maintenance dose. Such a dosing holiday may occur immediately after the loading dose is administered, or at any time during the administration of the maintenance dose. In some embodiments, the loading dose is 300 mg or less, 250 mg or less, 200 mg or less, 150 mg or less, 100 mg or less, 50 mg or less, 25 mg or less, 20 mg or less, 15 mg or less, 10 mg or less or 5 mg or less. In some embodiments, the loading dose is 300 mg, 250 mg, 200 mg, 150 mg, 100 mg, 50 mg, 25 mg, 20 mg, 15 mg, 10 mg, 5 mg, or 2 mg. In some embodiments, the maintenance dose is 300 mg or less; 200 mg or less, 100 mg or less, 50 mg or less, 25 mg or less, 20 mg or less, 15 mg or less, 10 mg or less, 5 mg or less, 2.5 mg or less, or 1 mg or less. In some embodiments, the maintenance dose is 300 mg, 250 mg, 200 mg, 100 mg, 50 mg, 25 mg, 20 mg, 15 mg, 10 mg, 5 mg, 2.5 mg, or 1 mg. Treatment

[0081] Some embodiments of the methods and compositions disclosed herein relate to methods for preventing, treating or improving one or more fatty liver diseases in a subject, the method comprising administering to a subject in need thereof an effective amount of a combination of Compound 1 described herein and one or more second agents. In some embodiments, fatty liver disease may be steatosis. In other embodiments, fatty liver disease may be non-alcoholic fatty liver disease. In some embodiments, fatty liver disease may be non-alcoholic steatohepatitis (NASH). In some embodiments, a subject may suffer from two or more of the above-mentioned fatty liver diseases.

[0082] Some embodiments of the methods and compositions disclosed herein relate to methods for reducing or preventing the deposition of extracellular matrix proteins, the methods comprising administering to a subject in need thereof an effective amount of a combination of compound 1 described herein and one or more second agents described herein. In some embodiments, the deposition of the extracellular matrix protein may include abnormal or excessive deposition of the protein. In some embodiments, the extracellular matrix protein may include one or more of collagen, keratin, elastin, or fibrin. In some embodiments, the extracellular matrix protein may include collagen. In some embodiments, the extracellular matrix protein may include type I collagen. In some embodiments, the extracellular matrix protein may include type Ia collagen. In some embodiments, the extracellular matrix protein may include type III collagen. Some embodiments of the compositions and methods disclosed herein relate to methods for treating fibrosis or its symptoms or sequelae, the methods comprising administering to a subject in need thereof an effective amount of a compound described herein.

[0083] In some embodiments, compounds and compositions comprising Compound 1 described herein and / or one or more second agents described herein can be used to treat a variety of conditions caused by fibrosis or inflammation, particularly including those associated with abnormal collagen deposition. Exemplary conditions include glycogen storage disease type III (GSD III), glycogen storage disease type VI (GSDVI), glycogen storage disease type IX (GSD IX), non-alcoholic fatty liver disease (NASH), cirrhosis, hepatitis, scleroderma, alcoholic fatty liver disease, atherosclerosis, asthma, cardiac fibrosis, organ transplant fibrosis, muscle fibrosis, pancreatic fibrosis, bone marrow fibrosis, liver fibrosis, hepatobiliary cirrhosis, splenic fibrosis, pulmonary fibrosis, idiopathic pulmonary fibrosis, diffuse parenchymal lung disease, idiopathic interstitial fibrosis, diffuse interstitial fibrosis, interstitial pneumonia, desquamative interstitial pneumonia, respiratory bronchiolitis, interstitial lung disease, chronic interstitial lung disease, acute interstitial pneumonia, hypersensitivity pneumonitis, nonspecific interstitial pneumonia, cryptogenic organizing pneumonia, lymphocytic interstitial pneumonia, pneumoconiosis, silicosis, emphysema, interstitial fibrosis, sarcoidosis, mediastinal fibrosis, cardiac fibrosis, atrial fibrosis, endomyocardial fibrosis, renal fibrosis, chronic kidney disease, type II Diabetes, macular degeneration, keloid lesions, hypertrophic scars, nephrogenic systemic fibrosis, injection fibrosis, surgical complications, fibrosis in transplanted organs, chronic allograft vasculopathy and / or chronic rejection, fibrosis associated with ischemia-reperfusion injury, post-vasectomy pain syndrome, fibrosis associated with rheumatoid arthritis, arthrofibrosis, Dupuytren's disease, dermatomyositis-polymyositis, mixed connective tissue disease, oral fibroproliferative lesions, fibrotic intestinal strictures, Crohn's disease, glial scars, leptomeningeal fibrosis, meningitis, systemic lupus erythematosus, fibrosis due to radiation exposure, fibrosis due to cystic rupture of the breast, myelofibrosis, retroperitoneal fibrosis, progressive massive fibrosis or symptoms or sequelae thereof, or other diseases or conditions that result in excessive deposition of extracellular matrix components (e.g., collagen).

[0084] In some embodiments, the method of the present disclosure includes a method for treating, improving or preventing a fibrotic condition. In some embodiments, the fibrotic condition may be secondary to another condition. In some embodiments, the fibrotic condition or primary condition may further include chronic inflammation of an organ, tissue, spatial region or fluid connection region of the subject's body. In some embodiments, the inflammation may include activating one or more TGF-β-dependent signaling pathways. In some embodiments, the TGF-β-dependent signaling pathway may include one or more elements that respond to T3 or T4. In some embodiments, the fibrotic condition may include abnormal or excessive deposition of one or more of collagen, keratin or elastin. In some embodiments, the fibrotic condition may include abnormal or excessive deposition of collagen. In some embodiments, the fibrotic condition may include abnormal or excessive deposition of type I collagen. In some embodiments, the fibrotic condition may include abnormal or excessive deposition of type Ia collagen. In some embodiments, the fibrotic condition may include abnormal or excessive deposition of type III collagen. In some embodiments, the fibrotic condition may include one or more of the following: glycogen storage disease type III (GSD III), glycogen storage disease type VI (GSD VI), glycogen storage disease type IX (GSD IX), non-alcoholic fatty liver disease (NASH), cirrhosis, hepatitis, scleroderma, alcoholic fatty liver disease, atherosclerosis, asthma, cardiac fibrosis, organ transplant fibrosis, muscle fibrosis, pancreatic fibrosis, bone marrow fibrosis, liver fibrosis, hepatobiliary cirrhosis, spleen fibrosis, scleroderma, pulmonary fibrosis, idiopathic pulmonary fibrosis, diffuse parenchymal lung disease, idiopathic interstitial fibrosis, diffuse interstitial fibrosis, interstitial pneumonia, desquamative interstitial pneumonia, respiratory bronchiolitis, interstitial lung disease, chronic interstitial lung disease, acute interstitial pneumonia, hypersensitivity pneumonitis, nonspecific interstitial pneumonia, cryptogenic organizing pneumonia, lymphocytic interstitial pneumonia, pneumoconiosis, silicosis, emphysema, interstitial fibrosis, sarcoidosis, mediastinal fibrosis, cardiac fibrosis, atrial fibrosis, heart Endomyocardial fibrosis, renal fibrosis, chronic kidney disease, type II diabetes, macular degeneration, keloid lesions, hypertrophic scars, nephrogenic systemic fibrosis, injection fibrosis, surgical complications, fibrosis in transplanted organs, chronic allograft vasculopathy and / or chronic rejection, fibrosis associated with ischemia-reperfusion injury, post-vasectomy pain syndrome, fibrosis associated with rheumatoid arthritis, arthrofibrosis, Dupuytren's disease, dermatomyositis-polymyositis, mixed connective tissue disease, oral fibroproliferative lesions, fibrotic intestinal strictures, Crohn's disease, glial scars, leptomeningeal fibrosis, meningitis, systemic lupus erythematosus, fibrosis due to radiation exposure, fibrosis due to cystic rupture of the breast, myelofibrosis, retroperitoneal fibrosis, progressive massive fibrosis.In some embodiments, the fibrotic condition may include one or more of: GSD III, GSD IX, non-alcoholic steatohepatitis, cirrhosis of the liver and / or pancreas, scleroderma, idiopathic pulmonary fibrosis, psoriasis, alcoholic fatty liver disease, Dupuytren's disease, and / or any combination thereof.

[0085] According to the methods and compositions disclosed herein, fibrotic conditions or conditions with fibrosis as sequelae may further include chronic inflammation. According to the methods and compositions disclosed herein, fibrotic conditions or conditions with fibrosis as sequelae may further include activation of one or more TGF-β-dependent signaling pathways. According to the methods and compositions disclosed herein, fibrotic conditions or conditions with fibrosis as sequelae may further include activation and / or inhibition of one or more thyroid receptor β (TRβ)-dependent signaling pathways. According to the methods and compositions disclosed herein, fibrotic conditions or conditions with fibrosis as sequelae may further include the participation of signaling pathways that respond to triiodothyronine (T3), thyroxine (T4), any combination thereof, or its mimetics. According to the methods and compositions disclosed herein, fibrotic conditions or conditions with fibrosis as sequelae may further include the participation of receptors that respond to T3, T4, any combination thereof, or its mimetics. In some embodiments according to the methods and compositions disclosed herein, fibrotic conditions or conditions with fibrosis as sequelae may include the participation of TRβ.

[0086] In some embodiments, the compositions and methods described herein provide compositions and methods for treating, improving, preventing or curing collagen deposition. In some embodiments, the collagen deposition includes abnormal or excessive deposition of collagen. In some embodiments, the collagen deposition may include abnormal or excessive deposition of type I collagen. In some embodiments, the collagen deposition may include abnormal or excessive deposition of type Ia collagen. In some embodiments, the collagen deposition may include abnormal or excessive deposition of type III collagen. According to the methods and compositions disclosed herein, the collagen deposition may further include the involvement of receptors that respond to T3, T4, any combination thereof, or their mimetics. In some embodiments according to the methods and compositions disclosed herein, the collagen deposition may include the involvement of TRβ. In some embodiments according to the methods and compositions disclosed herein, the collagen deposition may be prevented, improved or cured by administering one or more TRβ agonists.

[0087] In some embodiments, administration of a dosage form of Compound 1 as described herein results in a decrease in the expression of Cola1, Col3a1, αSMA and / or galectin 1 genes, or any combination thereof, or products thereof, in a subject to which the combination is administered. In some embodiments, administration of a dosage form of Compound 1 as described herein results in a decrease in the degree of fibrosis observable by histology, histochemistry, immunohistochemistry, etc., and / or a decrease in the amount, accumulation, or distribution of type 1 collagen and / or hydroxyproline, or any combination thereof, in a subject to which the combination is administered. In some embodiments, administration of a dosage form of Compound 1 as disclosed herein results in a decrease in total serum lipids, total serum cholesterol, total serum triglycerides, total liver lipids, total liver cholesterol, total liver triglycerides, or any combination thereof. Example

[0088] The compositions and methods described herein are further illustrated by the following non-limiting examples. Example 1: Preparation of spray-dried dispersion of compound 1

[0089] The following formulations were prepared and spray dried to form amorphous spray dried dispersions (SDD) for further testing: (a) 25 / 75 (w / w) Compound 1 / hydroxypropyl methylcellulose acetate succinate M form (HPMCAS-M); (b) 25 / 75 (w / w) Compound 1 / hydroxypropyl methylcellulose acetate succinate L form (HPMCAS-L); (c) 25 / 75 (w / w) Compound 1 / polyvinyl pyrrolidone-vinyl acetate copolymer (PVP-VA64); (d) 25 / 75 (w / w) Compound 1 / L100; and (e) (w / w) Compound 1 / HPMC E3.

[0090] These SDD intermediate preparations were spray dried on a Bend Lab dryer (BLD-35) with a 35kg / h drying gas flow rate capacity. The BLD-35 is a custom-made spray dryer to support batch sizes of 0.5 to <1kg batch sizes for early feasibility, pharmacokinetics and toxicology supply. The BLD-35 uses a pressure swirl nozzle to atomize the spray-dried solution into droplets, which are then dried with a heated nitrogen stream and collected using a cyclone. Manufacturing conditions are provided in Table 1. All five SDDs were successfully manufactured in high yields. Although a small amount of insoluble particles were noted in the acetone solution, they did not affect the process and were considered to be impurities or other non-compound 1 materials. The spray-dried dispersion exhibited a typical SDD morphology with no evidence of crystallization. Table 1: Manufacturing conditions of spray-dried dispersion of compound 1 Example 2: Water-soluble compound 1

[0091] The equilibrium solubility of crystalline Compound 1 in 0.01N HCl and PBS buffer (pH 6.5) at 37°C was evaluated by measuring the dissolved concentration of Compound 1 in saturated solutions in each respective medium. The experimental values ​​of solubility listed in Table 2 were obtained by measuring the concentration of the supernatant after centrifugation at 386,000 xg. Table 2: Solubility of amorphous compound 1

[0092] The amorphous solubility of amorphous Compound 1 was determined by slowly adding the API from an organic stock solution into an aqueous medium of interest. When amorphous solubility was reached, a drug-rich phase was formed and measured by scattering of UV / visible light and / or by dynamic light scattering (DLS) detection.

[0093] The solubility of amorphous Compound 1 was evaluated in PBS, pH 6.5 alone and in PBS, pH 6.5 containing 0.5% simulated intestinal fluid (SIF). Figure 1 The measured concentration of compound 1 from a methanol stock solution and light scattering are shown over time. The onset of scattering in the SIF-containing medium occurs after 180 μg / mL-210 μg / mL compound 1. In PBS alone, compound 1 precipitated once the stock solution was introduced into the medium, so no estimate of amorphous solubility was obtained. This is consistent with the initial solubility tests, where the crystalline solubility in PBS was very low in the absence of bile salts. Example 3: Solubility of spray-dried dispersion of Compound 1

[0094] SDD was evaluated in a non-sedimentation dissolution test designed to monitor dissolution rate and crystallization inhibition during transfer from simulated gastric medium to simulated intestinal medium. For the gastric-to-intestinal buffer (G-IB) transfer dissolution test, pH 2 ("gastric"; "G") medium was added to each sample at a target dose concentration of 1000 μg compound 1 / mL. After exposure to gastric medium for 30 minutes, concentrated simulated intestinal buffer was added to reach a final composition of 0.5% SIF in PBS, pH 6.5, and the dose concentration was halved (500 μg compound 1 / mL). This dose concentration was selected to be twice the estimated amorphous solubility in an attempt to simultaneously distinguish between dissolution rate and maintenance of supersaturation. Concentrations were monitored in situ by a UV fiber optic probe (stirring rate: 100 rpm), and concentrations were assessed by microcentrifugation (15,800 x g) or ultracentrifugation (300,000 x g). The microcentrifuge separated precipitates (undissolved drug) and completely dissolved drug. The completely dissolved drug is composed of three dissolved substances: freely dissolved drug ("free drug"), drug bound to bile salt micelles ("micelle-bound drug") and drug in small aggregates of about 50nm to 300nm in size ("colloidal drug"). Ultracentrifuge further separates colloidal drugs, and the supernatant contains only free drugs and micelle-bound drugs. These three species have different activities in vivo and can be used to help distinguish preparations. Free drug is the smallest species and is the only species that is considered to be directly distributed into the epithelial cell membrane. Once the absorbed free dissolved drug produces a concentration gradient, the micelle-bound drug can pass through the unstirred mucus boundary layer and the source free drug. Finally, drug-polymer colloids are the source of rapidly dissolved drugs and can penetrate the unstirred mucus boundary layer in some cases (Stewart et al.Mol.Pharmaceutics, 2017, 12, 2437-2449).

[0095] The results of the G-IB dissolution test are shown in Figure 2 and Table 3. All SDD formulations containing enteric polymers reached amorphous solubility within 10 minutes in enteric buffer. These dispersions also appeared to form colloids with 25 / 75 Compound 1 / HPMCAS-L SDD in IB, providing the highest concentration. In situ measurements of Eudragit containing SDD were inconsistent with the concentrations measured after centrifugation. A careful observation of the raw data from the UV probe showed a spectral shift for this sample, which led to erroneous measurements. The exact cause of this shift is currently unknown. It can be attributed to detector saturation caused by undissolved solids, or specific interactions between the drug and polymer in solution. All SDDs exhibited significantly improved dissolution compared to crystalline Compound 1. Table 3: G-IB dissolution of spray-dried dispersions of Compound 1 Example 4: Open Stability of Spray-Dried Dispersion of Compound 1

[0096] The SDD of Compound 1 was open aged at 40°C / 75% relative humidity (RH) for 2 weeks to provide a preliminary assessment of the chemical stability of the SDD of Compound 1. The stability samples were tested using HPLC using the method in Table 4. Table 4: HPLC method used for stability analysis Working concentration About 100 μg A / mL MPA (35%) 20 mM sodium phosphate (aq), pH 6.1 MPB (65%) ACN Thinner 7:3ACN:20mM sodium phosphate buffer column XBridge Shield RP18, 5μm, 4.6x 50mm Column temperature 30℃ Detection wavelength 280nm Flow rate 1mL / min Injection volume 10μL

[0097] Stability samples were tested for assay and related substances. The analytical results are listed in Table 5. For all SDD formulations, possible processing degradation was observed with an increase in total impurities ranging from 0.65% (HPMCAS-M SDD) to 1.42% (HPMCAS-L SDD). This was mainly due to impurities related to the API process. Table 5: HPLC open stability data of spray-dried dispersion of Compound 1

[0098] The dispersions containing PVP-VA showed the best chemical stability at 40°C and 75% RH. The neutral PVP-VA polymer is likely the least reactive with compound 1. The dispersions containing Eudragit and HPMC had the worst chemical stability at 40°C and 75% RH. This was mainly due to the growth of hydrolytic degradation products of compound 1 in the SDD containing Eudragit and the growth of unknown degradants in the SDD containing HPMC. Similar growth of total impurities was observed for the SDD containing HPMCAS-M and HPMCAS-L after opening for 2 weeks at 40°C and 75% RH. Example 5: Closed Stability Packaging Study of Spray-dried Dispersion of Compound 1

[0099] Due to the extensive degradation observed after 2 weeks of opening at 40°C / 75% RH, stability studies were initiated for Compound 1 SDD under closed and dry conditions. The samples were evaluated for stability at 2 weeks, 6 weeks, and 3 months when stored in 4 mL scintillation vials and sealed in 60 cc HDPE bottles (with heat induction seals and 0.5 g desiccant).

[0100] The chemical stability of compound 1 SDD after 2 weeks under closed conditions was evaluated by HPLC using the method provided in Table 4 of this article. The SDD containing PVP-VA showed the best chemical stability after 2 weeks under closed conditions, with little or no degradation observed. Among the SDDs with enteric (acidic) polymers, the SDD based on HPMCAS-M provided the best chemical stability characteristics. All SDDs containing cellulose polymers showed the same impurity growth after 2 weeks of 40 / 75 closure. Upon closer inspection, this impurity was present in the incoming API at a level below the threshold for binding. Dispersions containing HPMC showed the worst chemical stability under closed conditions. Dispersions containing Eudragit had a moderate chemical stability risk when closed at 40 / 75, with a slight increase in hydrolytic degradation products of compound 1 and unknown impurities after 2 weeks. Further evidence of unknown degradation products that may have been formed during manufacturing and co-eluted with known synthetic impurities was observed. Table 6 provides the closed stability degradation data at two weeks, while Table 7 provides the closed stability degradation data at six weeks. Furthermore, no changes in the particle morphology and crystallinity of SDD were observed after 6 weeks at 40°C / 75%RH. Table 6: HPLC 2-week occlusion stability data of spray-dried dispersion of Compound 1 Table 7: HPLC 6-week occluded stability data of spray-dried dispersion of Compound 1 Example 6: Closed Stability Packaging Study of PVP-VA SDD of Compound 1

[0101] The chemical stability of the PVP-VA containing SDD of compound 1 under closed conditions was evaluated by HPLC using the method provided in Table 4 herein. After 3 months of storage under closed conditions, minimal degradation of the 25 / 75 (w / w) compound 1 PVP-VA SDD was observed. The 6-week analysis of the 25 / 70 / 5 (w / w / w) compound 1 / PVP-VA / Poloxamer 407 SDD also showed good chemical stability. The stability data of the PVP-VA containing SDD of compound 1 is provided in Table 8. Table 8: Occlusion stability data of dry dispersions of compound 1 containing PVP-VA Example 7: Tablet Formulation of Compound 1

[0102] Tablets are prepared by combining all intragranular materials (i.e., active intermediates, ductile fillers, brittle fillers, disintegrants and glidants) except lubricants and mixing the materials for 60 turns at 16 rpm in a 16-quart V-shell blender to form a premix. The premix is ​​then de-agglomerated (delumped) by mixing at a speed of 1500+ / -100rpm using a round-milled impeller using a 032R sieve through a Quadro Comil Model U5. The de-agglomerated material is then returned to the 16-quart V-shell blender and mixed or turned 180 turns at 16rpm to form a pre-granulated main blend. The pre-granulated blend prepared according to this embodiment has a high bulk density and compaction and a relatively low Carr index, indicating that the pre-granulated blend should have acceptable flow characteristics for roller compaction. It is also found that the pre-granulated blend is highly compressible, tabletable and compactable.

[0103] The intragranular lubricant was added to the pre-granulation master mix, hand mixed for about 15 to 30 seconds, then returned to the blender through a #20 mesh screen and mixed at 16 rpm for 48 revolutions to form a master lubricant pre-granulation mix. The master lubricant pre-granulation mix was roller compacted using a Gerties Mini-Pactor using the settings in Table 9 to form an intragranular mix. Table 9: Roller settings

[0104] The extragranular disintegrant was added to the intragranular mixture and mixed for 180 turns at 18 rpm in an 8 quart V-shell blender to form an extragranular main mixture. The extragranular lubricant was passed through a #20 mesh screen, added to the extragranular main mixture and mixed for 48 turns at 18 rpm to form an extragranular lubricant mixture. The extragranular mixture prepared according to this embodiment had a high bulk density and compaction and a relatively low Carr index, indicating that the pregranulated mixture should have acceptable flow characteristics for roller compaction.

[0105] The extragranular lubricant mixture was then compressed on a Korsch XL100 tablet press (9 / 32" SRC tooling, Sotax ST50 tablet hardness tester) to form tablets with a target weight of 150 mg. The tablet press was adjusted as necessary to achieve the target tablet weight and hardness. The tablets were then dusted using a vibratory and / or vacuum dust collector. The compression parameters are provided below.

[0106] Two rounds of formulation and manufacturing were performed. The first round, "Round A," focused on identifying formulations for use with Compound 1 / PVP-VA6425 / 75 (w / w) spray-dried dispersions. The selection of brittle fillers and disintegrants was varied to evaluate the disintegration time and stability performance of the formulations. "Round B," which evaluated the formulations, replaced lactose monohydrate with anhydrous lactose to evaluate whether different lactose forms resulted in different stability results within the tablets. Tablets A1, A2, A3, and B1 were determined to have acceptable brittleness and dissolution properties. The formulations are summarized in Table 10. Formulations C1 and C2 are additional manufacturing batches and have the same composition as Formulation A1. Table 10: Tablet formulation of Compound 1

[0107] Tablets A1, A2, A3 and B1 were evaluated in the USPII sedimentation dissolution test with 1 wt% sodium lauryl sulfate (SLS) at 50° C. All tablets showed that the average release of the formulation was adequate, with formulations A1, A2 and B1 having greater than 80% release after ten minutes. Example 8: Stability of tablet formulation

[0108] The tablet formulations were subjected to stability studies. The tablets were packaged in heat sealed HDPE bottles with minimal head space and stored in a temperature controlled stability chamber at 50°C, 40°C and 25°C and 5°C. The conditions for each specific formulation are listed in Table 11 below.

[0109] An overall comparison of the tablet formulations indicated that Formulation A1 was the most chemically stable as it exhibited the smallest change in total impurities between t=0 and 1 month under either condition. Table 11: Tablet formulation stability *Current clinical dosage form

[0110] With respect to the use of substantially any plural and / or singular terms herein, those skilled in the art may translate from the plural to the singular and / or from the singular to the plural as the context and / or application requires. For clarity, various singular / plural arrangements may be expressly presented herein.

[0111] Those skilled in the art will understand that the terms generally used herein, and particularly in the appended claims (e.g., the bodies of the appended claims), are generally intended to be "open" terms (e.g., the term "including" should be interpreted as "including but not limited to," the term "having" should be interpreted as "having at least," the term "includes" should be interpreted as "including but not limited to," etc.). Those skilled in the art will further understand that if a specific number of claims is intended to be referenced, such intent will be expressly stated in the claim, and in the absence of such a statement, no such intent is present. For example, as an aid to understanding, the following appended claims may contain the use of the introductory phrases "at least one" and "one or more" to introduce claim expressions. However, the use of such phrases should not be interpreted as implying that the introduction of a claim recitation by the indefinite article "a" or "an" limits any particular claim containing such introduced claim recitation to embodiments containing only one such recitation, even when the same claim includes the introductory phrases "one or more" or "at least one" and an indefinite article such as "a" or "an" (e.g., "a" and / or "an" should be interpreted as meaning "at least one" or "one or more"); the same is true for the use of definite articles used to introduce claim recitations. Furthermore, even if a specific number of introduced claim recitations is explicitly stated, those skilled in the art will recognize that such a statement should be interpreted as meaning at least the number of the recitations (e.g., the basic statement "two recitations" without other modifications means at least two recitations, or two or more recitations). Furthermore, in those instances where a convention similar to “at least one of / at least one of A, B, and C, etc.” is used, such construction is generally intended to mean that a person skilled in the art will understand the convention (e.g., “a system having at least one of A, B, and C” will include but is not limited to systems having A alone, B alone, C alone, A and B together, A and C together, B and C together, and / or A, B, and C together, etc.). In those instances where a convention similar to “at least one of / at least one of A, B, or C, etc.” is used, such construction is generally intended to mean that a person skilled in the art will understand the convention (e.g., “a system having at least one of A, B, or C” will include but is not limited to systems having A alone, B alone, C alone, A and B together, A and C together, B and C together, and / or A, B, and C together, etc.).Those skilled in the art will further understand that almost any disjunctive word and / or phrase indicating two or more optional terms, whether in the specification, claims or drawings, should be understood to include the possibility of one of these terms, any of these terms, or both of these terms. For example, the phrase "A or B" will be understood to include the possibility of "A" or "B" or "A and B".

[0112] In addition, where features or aspects of the disclosure are described in terms of Markush groups, those skilled in the art will recognize that the disclosure is also thereby described in terms of any individual member or subgroup of members of the Markush group.

[0113] As will be understood by those skilled in the art, for any and all purposes, for example, in terms of providing a written description, all ranges disclosed herein also encompass any and all possible sub-ranges and combinations of sub-ranges thereof. Any listed range can be easily considered to fully describe and enable the same range to be decomposed into at least equal half, one-third, one-quarter, one-fifth, one-tenth, etc. As a non-limiting example, each range discussed herein can be easily decomposed into lower third, middle third, and upper third, etc. As will be understood by those skilled in the art, all languages ​​such as "at most", "at least", "greater than", "less than", etc. include the numbers listed, and refer to the ranges that can be subsequently decomposed into sub-ranges as described above. Finally, as will be understood by those skilled in the art, ranges include each individual member. Therefore, for example, a group with 1 to 3 articles refers to a group with 1, 2 or 3 articles. Similarly, a group with 1 to 5 articles refers to a group with 1, 2, 3, 4 or 5 articles, etc.

[0114] Although various aspects and embodiments have been disclosed herein, other aspects and embodiments will be apparent to those skilled in the art. The various aspects and embodiments disclosed herein are for illustrative purposes and are not intended to be limiting, with the true scope and spirit being indicated by the appended claims.

Claims

1. An oral dosage form comprising: (A) A composition comprising a compound 1 having the following structure: or a pharmaceutically acceptable salt thereof; and One or more polymers selected from the group consisting of polyvinyl pyrrolidone (PVP), polyvinyl pyrrolidone-vinyl acetate copolymer (PVP-VA), polyvinyl alcohol (PVA), polyacrylic acid (PAA), polyethylene oxide (PEO), hydroxypropyl cellulose (HPC), hydroxypropyl methylcellulose (HPMC), copovidone, poloxamer 407, hydroxypropyl methylcellulose acetate succinate (HPMCAS), polyacrylates, and combinations thereof; and (B) one or more ductile fillers, brittle fillers, disintegrants, glidants, lubricants or combinations thereof.

2. The oral dosage form according to claim 1, wherein the polymer is polyvinylpyrrolidone-vinyl acetate copolymer (PVP-VA).

3. The oral dosage form of claim 1 or claim 2, wherein Compound 1 and the one or more polymers are combined to form a spray-dried dispersion.

4. The oral dosage form of claim 1 or claim 2, wherein Compound 1 and the one or more polymers are combined to form a hot melt extrudate.

5. The oral dosage form according to any one of claims 1 to 4, wherein the mass ratio of Compound 1 to the one or more polymers in the composition is 1:10 to 10:

1.

6. The oral dosage form according to claim 5, wherein the mass ratio of Compound 1 to the one or more polymers in the composition is 1:1 to 1:

4.

7. The oral dosage form according to claim 5 or 6, wherein the mass ratio of Compound 1 to the one or more polymers in the composition is 1:

3.

8. The oral dosage form according to any one of claims 1 to 7, wherein the composition comprises 5% to 25% by weight of the dosage form.

9. The oral dosage form of claim 8, wherein the composition comprises 10% to 15% by weight of the dosage form.

10. The oral dosage form according to any one of claims 1 to 9, wherein the ductile filler is selected from microcrystalline cellulose and silicified microcrystalline cellulose.

11. The oral dosage form according to any one of claims 1 to 10, wherein the ductile filler is microcrystalline cellulose.

12. The oral dosage form of claim 11, wherein the microcrystalline cellulose comprises 40% to 60% by weight of the dosage form.

13. The oral dosage form of claim 12, wherein the microcrystalline cellulose comprises 45% to 55% by weight of the dosage form.

14. The oral dosage form of claim 13, wherein the microcrystalline cellulose comprises 50% by weight of the dosage form.

15. The oral dosage form according to any one of claims 1 to 14, wherein the friable filler comprises lactose monohydrate, spray-dried lactose, anhydrous lactose, lactose monohydrate, anhydrous lactose, mannitol, and combinations thereof.

16. The oral dosage form according to any one of claims 1 to 15, wherein the brittle filler comprises lactose monohydrate, anhydrous lactose or mannitol.

17. The oral dosage form according to any one of claims 1 or 16, wherein the brittle filler comprises 10% to 40% by weight of the dosage form.

18. The oral dosage form according to any one of claims 1 or 17, wherein the brittle filler comprises 20% to 30% by weight of the dosage form.

19. The oral dosage form according to any one of claims 1 or 18, wherein the brittle filler comprises 25% by weight of the dosage form.

20. The oral dosage form according to any one of claims 1 to 19, wherein the disintegrant is selected from carboxymethylcellulose calcium, sodium carboxymethyl starch, cross-linked sodium carboxymethyl cellulose, starch, pregelatinized starch, sodium starch glycolate, cross-linked polyvinyl pyrrolidone crospovidone, hydroxypropyl cellulose, magnesium aluminum silicate and polyclinic potassium.

21. The oral dosage form according to any one of claims 1 to 20, wherein the disintegrant is croscarmellose sodium or crospovidone.

22. The oral dosage form according to any one of claims 1 to 21, wherein the disintegrant comprises 5% to 15% by weight of the dosage form.

23. The oral dosage form according to any one of claims 1 to 22, wherein the disintegrant comprises 10% by weight of the dosage form.

24. The oral dosage form according to any one of claims 1 to 23, wherein the lubricant is selected from the group consisting of stearic acid, talc, glyceryl behenate, sodium stearyl fumarate and magnesium stearate.

25. The oral dosage form according to any one of claims 1 to 24, wherein the lubricant is magnesium stearate.

26. The oral dosage form according to any one of claims 1 to 25, wherein the lubricant comprises 0.1 wt% to 3 wt% of the dosage form.

27. The oral dosage form according to any one of claims 1 to 26, wherein the lubricant comprises 0.1 wt% to 1 wt% of the dosage form.

28. The oral dosage form according to any one of claims 1 to 27, wherein the lubricant comprises 5% by weight of the dosage form.

29. The oral dosage form according to any one of claims 1 to 28, wherein the glidant is silicon dioxide, starch or talc.

30. The oral dosage form according to any one of claims 1 to 29, wherein the glidant is silicon dioxide.

31. The oral dosage form according to any one of claims 1 to 30, wherein the glidant comprises 0.1 wt% to 3 wt% of the dosage form.

32. The oral dosage form according to any one of claims 1 to 30, wherein the glidant comprises 0.1 wt% to 1 wt% of the dosage form.

33. The oral dosage form according to any one of claims 1 to 30, wherein the glidant comprises 5% by weight of the dosage form.

34. An oral dosage form according to any one of claims 1 to 33, comprising: (a) an intragranular portion comprising: (i) Compound 1 or a pharmaceutically acceptable salt thereof and the one or more polymers; (ii) a ductile filler; (iii) a brittle filler; (iv) a disintegrant; (v) a glidant and (vi) a lubricant; and (b) an extragranular portion comprising (i) a disintegrant and (ii) a lubricant.

35. The oral dosage form of any one of claims 1 to 34, wherein the dosage form is characterized by having 90% to 100% of the original amount of Compound 1 after storage for 1 month at 50°C and ambient relative humidity (RH).

36. The oral dosage form according to any one of claims 1 to 35, wherein the dosage form is characterized by having 95% to 100% of the original amount of Compound 1 after storage for 1 month at 50°C and ambient relative humidity (RH).

37. The oral dosage form of any one of claims 1 to 34, wherein the dosage form is characterized by having 90% to 100% of the original amount of Compound 1 after storage for 2 months at 50°C and ambient relative humidity (RH).

38. The oral dosage form of any one of claims 1 to 35, wherein the dosage form is characterized by having 95% to 100% of the original amount of Compound 1 after storage for 2 months at 50°C and ambient relative humidity (RH).

39. A method for preparing the oral dosage form of any one of claims 1 to 38, comprising the steps of: (a) preparing a pre-granulated premix, the pre-granulated premix comprising (a) a composition comprising compound 1 and the one or more polymers; (ii) a ductile filler; (iii) a friable filler; (iv) a disintegrant and (v) a glidant; (b) mixing the premixed composition; (c) further adding a lubricant to the pre-granulated premix; (d) compacting the pre-granulated premix; and (e) granulating the pregranulated premix to form a granulated material.

40. The method according to claim 39, further comprising the steps of: (f) adding a disintegrant to the granulated material; (g) further mixing the granulated material; (h) further adding a lubricant to the granulated material and mixing to form a final mixture; and (i) compressing the final mixture into a dosage form.

41. A method of preventing, treating, or ameliorating one or more fatty liver diseases in a subject in need thereof, the method comprising administering to the subject the oral dosage form of any one of claims 1 to 38.

42. The method of claim 41, wherein the fatty liver disease is selected from the group consisting of steatosis, nonalcoholic fatty liver disease, and nonalcoholic steatohepatitis.

43. The method of claim 41 or 42, wherein the method comprises administering a second agent.

44. The method of claim 43, wherein the second agent is administered sequentially or simultaneously.

45. The method of any one of claims 41 to 44, wherein the method results in the prevention, treatment or amelioration of fibrosis, a fibrotic condition or a fibrotic symptom.

46. ​​The method of any one of claims 41 to 45, wherein the method results in a reduction in the amount of extracellular matrix protein present in one or more tissues of the subject.

47. The method of any one of claims 41 to 46, wherein the method results in a reduction in the amount of collagen present in one or more tissues of the subject.

48. The method of claim 47, wherein the method results in a decrease in the amount of type I, type Ia, or type III collagen present in one or more tissues of the subject.